CN108658985A - A kind of alkaloid compound and application containing double lactams - Google Patents

A kind of alkaloid compound and application containing double lactams Download PDF

Info

Publication number
CN108658985A
CN108658985A CN201710191160.2A CN201710191160A CN108658985A CN 108658985 A CN108658985 A CN 108658985A CN 201710191160 A CN201710191160 A CN 201710191160A CN 108658985 A CN108658985 A CN 108658985A
Authority
CN
China
Prior art keywords
group
base
aliphatic
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710191160.2A
Other languages
Chinese (zh)
Inventor
邵长伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocean University of China
Original Assignee
Ocean University of China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean University of China filed Critical Ocean University of China
Priority to CN201710191160.2A priority Critical patent/CN108658985A/en
Publication of CN108658985A publication Critical patent/CN108658985A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/008—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by two hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a kind of alkaloid compounds containing double lactams, or non-equal amount of mixture, geometric isomer, solvate, pharmaceutically acceptable salt or the prodrug of its tautomer, stereoisomer, racemic modification, enantiomter, and the pharmaceutical composition comprising the compound.The invention also discloses this kind of compound and its pharmaceutical composition as drug especially as the purposes with immunoloregulation function and anti-inflammatory, anti-fibrosis drug.

Description

A kind of alkaloid compound and application containing double lactams
Technical field
The invention belongs to drug fields, and are specifically related to a kind of alkaloid compound and its drug containing double lactams Composition and alkaloid compound containing double lactams and its pharmaceutical composition are as drug, especially as with exempting from The purposes of epidemic disease regulatory function and anti-inflammatory, anti-fibrosis drug.
Background technology
Immunological regulation refers to the immunocyte in immune system and between immune molecule, and with other systems such as nerve Interaction between internal system so that immune response maintains optimal level in the form of most appropriate.It is immune to adjust Section can liken the symphony orchestra of body to, work good-identify and remove antigen, generate immune tolerance to self component, maintain The stabilization of interior environment.Work poor-cause pathogeny imcrobe infection, tumour, autoimmunity disease, immunologic deficiency disease, hypersensitivity.It is immune to adjust Section is to rely on immune system（Immune system）Come what is realized.
The gene of encoding inflammatory molecules is NF- κ B reactive groups, to these inflammatory molecules transcription regulation and control be NF- κ B most Main function, and the earliest and extensive content of research.Many factors can activate Nuclear Factor kappa B, make it from cell Matter indexing is in nucleus, so as to cause a series of inflammatory reactions.Therefore the overactivity of NF- κ B is inhibited to be likely to become treatment inflammation The preferable method of disease.The activation of NF- κ B can be induced by having now been found that many factors, including tumor necrosis factor (TNF-a), white Interleukin-β, lipopolysaccharides (LPS), oxidant, radioactive ray, ultraviolet light, virus and its metabolite etc..Antigen receptor crosslinking, calcium from Subcarrier, protein kinase PKC, antigen, phytolectin PHA, canavalin ConA etc. and cell division, the related factor of proliferation It can promote the activation of NF- κ B.
Inflammation is a kind of defense reaction of the body to infection, and under normal physiological conditions, inflammation is beneficial to body. Under pathological conditions, inflammation can also cause a series of pathological changes, can cause to damage to body, such as arthritis, septicemia, group Knit organ fibrosis and atherosclerosis etc..When body is damaged, macrophage is as first of immune defence line, meeting Release a series of cellular inflammation factors, including tumor necrosis factor（Tumor necrosis factor, TNF), leucocyte Interleukin（Interleukin, IL), prostaglandin 2 (Prostaglandin E2, PGE2) and nitric oxide（Nitric Oxide, NO) etc., these inflammatory factors have great influence to the repair process of body.Inflammation causes parenchymatous disease cell to be sent out Raw necrosis organizes the pathologic process of extracellular matrix abnormal increase and over-deposit, less serious case to become fibrosis, and severe one causes Institutional framework is destroyed and organ sclerosis occurs.
Organ-tissue fibrosis less serious case is known as fibrosis, and severe one causes institutional framework to destroy and organ sclerosis occurs.Tissue Fibrosis not only occurs on the organs such as lung, liver, and tissue fibrosis can involve the almost all of organ of human body and system, it be by In many reasons（Such as inflammation, immune, poisonous substance, ischemic and hemodynamic responses etc.）Cause parenchymal cell destruction, then leads It causes the inflammation deformation of parenchyma, necrosis and activates corresponding macrophage release cytokine profiles and growth factor, this The extracellular matrix of a little factor activator quiescent conditions（Extracellular martri, ECM) cell is generated, it is allowed to be converted into Myofibroblast;Myofibroblast is proliferated, and secrete cytokines, is remake by paracrine mode thin for macrophage Born of the same parents.Myofibroblast can synthesize the ECM ingredients such as a large amount of collagens, while ECM degradations are reduced, to cause organ or tissue fine Dimensionization.
Since each organ or tissue's function, the difference of form, and each organ or tissue mainly form the difference of cell, So that Different Organs or the fibrosis of tissue in its pathogenesis existing general character, also have individual character;Cell is mainly generated with ECM For, it is hepatic stellate cells in liver, is mesangial cell in glomerulus, is renal interstitial in renal interstitial into fiber finer Born of the same parents, are lung fibroblast in lungs, are cardiac fibroblasts in heart, are Peritoneal Mesothelial Cells in peritonaeum.Therefore, exist There is also certain differences in the pathogenesis and therapy target of Different Organs or tissue fibrosis.
Invention content
The alkaloid compound containing double lactams of a kind of Formulas I, Formula II structure, tautomer, alloisomerism Body, racemic modification, the non-equal amount of mixture of enantiomter, geometric isomer, solvate, pharmaceutically acceptable salt or its The solvate of salt, it is characterised in that Formulas I, Formula II compound have the following structure：
,
R1, R2, R3And shown in A, B be defined as follows：
A, B are five yuan or hexa-atomic of aromatic ring or hetero-aromatic ring, saturated or unsaturated carbocyclic ring or carbon heterocyclic; “" it is single Key is not present;N=0,1,2,3 or 4;K=0,1,2,3 or 4;
Each R1, R3Can be identical or different, it is each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carboxylic Base, alkyl, halogenated alkyl, alkoxy, alkylamino, alkyl acyl, hydroxy alkoxy base, Hydroxyalkylamino, hydroxyl alkane Acyl group, halogenated alkoxy, halogenated alkylamino, ohaloalkanoyl, aminoalkoxy, naphthenic base, cycloalkyl oxy, ring Alkyl amino, cycloalkanoyl, alkenyl, alkenylalkoxy, alkenyl alkylamino, alkenyl alkanoyl, alkynyl, alkynyl alkane Oxygroup, alkynyl alkylamino, alkynyl alkanoyl, aryl, aryloxy group, aroyl, fragrant amino, alkoxy aryl, aryl Alkylamino, heteroaryl, heteroaryloxy, 4-hetaroylpyrazol, heteroaryl amino, heteroarylalkoxy, heteroarylalkylamino are miscellaneous Ring group alkanoyl, Heterocyclylalkyl, heterocycle oxygroup, heterocyclylamino group, heterocyclylacyl, heterocyclylalkoxy, heterocycle Base alkylamino, heterocycle alkanoyl, azido alkoxy, condensed-bicyclic base condense miscellaneous bicyclic group, condensed-bicyclic base fat Fat race, condensed miscellaneous bicyclic group aliphatic, condensed-bicyclic base oxygroup, condensed miscellaneous bicyclic group oxygroup, condensed-bicyclic base amino, Miscellaneous bicyclic group amino is condensed, condensed-bicyclic base alkoxy condenses miscellaneous bicyclic group alkoxy, and condensed-bicyclic base alkylamino is thick Miscellaneous bicyclic group alkylamino is closed, condensed-bicyclic base oxygroup alkoxy condenses miscellaneous bicyclic group oxygroup alkoxy, condensed-bicyclic base ammonia Base alkoxy, condenses miscellaneous bicyclic group aminoalkoxy, and condensed-bicyclic base-C (=O)-, condensed-bicyclic base-C (=O) O- are condensed Miscellaneous bicyclic group-C (=O)-condenses miscellaneous bicyclic group-C (=O) O-, condensed-bicyclic base amino-C (=O)-, condenses miscellaneous bicyclic group ammonia Base-C (=O)-, condensed-bicyclic base-C (=O) N (R4)-, condenses miscellaneous bicyclic group-C (=O) N (R4)-, spiral shell bicyclic group, spiral shell are miscellaneous double Ring group, spiral shell bicyclic group aliphatic, the miscellaneous bicyclic group aliphatic of spiral shell, spiral shell bicyclic group oxygroup, the miscellaneous bicyclic group oxygroup of spiral shell, spiral shell are bicyclic Base amino, the miscellaneous bicyclic group amino of spiral shell, spiral shell bicyclic group alkoxy, the miscellaneous bicyclic group alkoxy of spiral shell, spiral shell bicyclic group alkylamino, spiral shell Miscellaneous bicyclic group alkylamino, spiral shell bicyclic group oxygroup alkoxy, the miscellaneous bicyclic group oxygroup alkoxy of spiral shell, spiral shell bicyclic group aminoalkoxy, The miscellaneous bicyclic group aminoalkoxy of spiral shell, spiral shell bicyclic group-C (=O)-, spiral shell bicyclic group-C (=O) O-, the miscellaneous bicyclic group-C of spiral shell (=O)-, Miscellaneous bicyclic group-the C of spiral shell (=O) O-, spiral shell bicyclic group amino-C (=O)-, the miscellaneous bicyclic group amino-C of spiral shell (=O)-, spiral shell bicyclic group-C (= O)N(R4Miscellaneous bicyclic group-the C of)-, spiral shell (=O) N (R4)-, R5R4N-, -C(=O)NR4R5, -OC(=O)NR4R5, -OC(=O)OR4, -N(R4)C(=O)NR4R5, -N(R4)C(=O)OR5, -N(R4)C(=O)-R5, R4R5N-S(=O)t-, R4S(=O)t-, R4S(= O)tN(R5)-, R5R4N- alkyl, R4S(=O)tAlkyl, R4R5N-C (=O)-alkyl, R5R4N- alkoxies, R4S(=O)tAlkane Oxygroup, R4R5N-C (=O)-alkoxy, aryl-(CH2)p-G-(CH2)m, heteroaryl-(CH2)p-G-(CH2)m, heterocycle- (CH2)p-G-(CH2)m, or naphthenic base-(CH2)p-G-(CH2)m, wherein G is O, S, NR6, S(=O), S(=O)2,C(= O), -C(=O)N(R4)-, -OC(=O)N(R4)-, -OC(=O)-, -N(R4)C(=O)N(R4)-, -(R4)N-S(=O)t-, - OS(=O)t, or-OS (=O)tN(R4)-;T is l or 2;P and m is each independently 0, l, 2,3 or 4;Or it is wherein fragrant Base-(CH2)p-G-(CH2)m, heteroaryl-(CH2)p-G-(CH2)m, heterocycle-(CH2)p-G-(CH2)m, or naphthenic base- (CH2)p-G-(CH2)mCan F, Cl, Br, I, alkyl, alkenyl, alkynyl, alkoxy or cyanogen be selected from by one or more The substituent group of base replaces.
R2For hydrogen, alkyl, halogenated alkyl, alkyl acyl, hydroxyalkanoyl, ohaloalkanoyl, naphthenic base, ring Alkyl acyl, alkenyl, alkenyl alkanoyl, alkynyl, alkynyl alkanoyl, aryl, aroyl, heteroaryl, 4-hetaroylpyrazol, Heterocycle alkanoyl, Heterocyclylalkyl, heterocyclylacyl, heterocycle alkanoyl, azido alkyl, condensed-bicyclic base are thick Miscellaneous bicyclic group is closed, condensed-bicyclic base-C (=O)-condenses miscellaneous bicyclic group-C (=O)-, and condensed-bicyclic base amino-C (=O)-is thick Close miscellaneous bicyclic group amino-C (=O)-, spiral shell bicyclic group, the miscellaneous bicyclic group of spiral shell, spiral shell bicyclic group aliphatic, the miscellaneous bicyclic group fat of spiral shell Race, spiral shell bicyclic group-C (=O)-, the miscellaneous bicyclic group-C of spiral shell (=O)-, spiral shell bicyclic group amino-C (=O)-, the miscellaneous bicyclic group amino-C of spiral shell (=O)-, -C(=O)NR4R5, R4R5N-S(=O)t-, R4S(=O)t-, R5R4N- alkyl, R4S(=O)tAlkyl, R4R5N-C (=O)-alkyl, aryl-(CH2)p-G-(CH2)m, heteroaryl-(CH2)p-G-(CH2)m, heterocycle-(CH2)p-G- (CH2)m, or naphthenic base-(CH2)p-G-(CH2)m, wherein G is O, S, NR6, S(=O), S(=O)2,C(=O), -C(= O)N(R4)-, -OC(=O)N(R4)-, -OC(=O)-, -N(R4)C(=O)N(R4)-, -(R4)N-S(=O)t-, -OS(=O )t, or-OS (=O)tN(R4)-;T is l or 2;P and m is each independently 0, l, 2,3 or 4;Or aryl-therein (CH2)p-G-(CH2)m, heteroaryl-(CH2)p-G-(CH2)m, heterocycle-(CH2)p-G-(CH2)m, or naphthenic base- (CH2)p-G-(CH2)mCan F, Cl, Br, I, cyano, alkyl, alkenyl, alkynyl, alcoxyl be selected from by one or more Base, aryl, heteroaryl, carbocylic radical, the substituent group substitution of heterocycle.
R6Can be identical or different, it is each independently hydrogen, R4R5NC(=O)-, R4OC(=O)-, R4C(=O)-, R4R5NS(=O)-, R4OS(=O)-, R4S(=O)-, R4R5NS(=O)2-, R4OS(=O)2-, R4S(=O)2, aliphatic, halogen Fat subsitutes race, hydroxyl group aliphatic, amino aliphatic, alkoxy aliphatic, alkylamino aliphatic, alkylthio group aliphatic, Aromatic yl aliphat, heteroaryl aliphatic, heterocycle aliphatic, naphthenic base aliphatic, aryloxy group aliphatic, heterocyclyloxy Base aliphatic, cycloalkyl oxy aliphatic, fragrant amino aliphatic, heterocyclylamino group aliphatic, cycloalkyl amino aliphatic, Aryl, heteroaryl, heterocycle or carbocylic radical.
Each R4And R5It independently is hydrogen, aliphatic, halogenated aliphatic, hydroxyl group aliphatic, amino aliphatic, alkoxy Aliphatic, alkylamino aliphatic, alkylthio group aliphatic, aromatic yl aliphat, heteroaryl aliphatic, heterocycle aliphatic, Naphthenic base aliphatic, aryloxy group aliphatic, heterocycle oxygroup aliphatic, cycloalkyl oxy aliphatic, fragrant amino aliphatic, Heterocyclylamino group aliphatic, cycloalkyl amino aliphatic, aryl, heteroaryl, heterocycle or naphthenic base;Work as R4And R5It is connected in R on the same nitrogen-atoms4, R5It can be randomly formed substituted or non-substituted 3-6 membered rings, condensed-bicyclic or spiral shell with nitrogen-atoms It is bicyclic;The hetero atom in heterocycle, heteroaryl, condensed miscellaneous bicyclic group, the miscellaneous bicyclic group of spiral shell involved in above-mentioned group is independently The 1-5 hetero atom in N, O, S, Se.
Above-mentioned R1, R2, R3, R4, R5, R6Group can appoint by deuterium, halogen, hydroxyl, methylol, carboxyl, acetyl Amino, alkyl（Such as methyl, ethyl, propyl）, alkoxy（Such as methoxyl group, ethyoxyl, tert-butoxy）, alkylamino, cycloalkanes Base, alkenyl, alkynyl, trifluoromethyl, trifluoroacetyl group, sulfydryl, halogen, nitro, amino, azido (- N3), Guanidine radicals, cyano, tertbutyloxycarbonyl (- Boc), carbonyl (- C=O), oxo (=O) is thio (=S), sulfonyl, virtue Base, heteroaryl, the substitution of one or more of heterocycle.
In some embodiments, compound of the present invention is general formula III-X compounds represented, or general formula Stereoisomer geometric isomer, tautomer, nitrogen oxides, raceme, hydrate, the solvent of compound shown in III-X Compound, metabolite, pharmaceutically acceptable salt or prodrug：
,
Wherein T1, T2, T3, T4Separate is CR1Or N, V1, V2, V3, V4Separate is CR3Or N, wherein T1, T2, T3, T4At most there are three can be N, V1, V2, V3, V4At most can there are two be N, "" indicate singly-bound Or it is not present;Each R1, R2, R3As follows：
Each R1, R3Can be identical or different, it is each independently H, F, Cl, Br, I, hydroxyl, amino, nitro, cyanogen Base, carboxyl, C1-C20 alkyl, C1-C20 halogenated alkyls, C1-C20 alkoxies, C1-C20 alkylaminos, C1-C20 alkyl Acyl group, hydroxyl C1-C20 alkoxies, hydroxyl C1-C20 alkylaminos, hydroxyl C1-C20 alkanoyls, C1-C20 halogenated alkoxies, The halogenated alkylaminos of C1-C20, C1-C20 ohaloalkanoyls, C1-C20 aminoalkoxies, C3-C10 naphthenic base, C3-C10 rings Alkyl oxy, C3-C10 cycloalkyl aminos, C3-C10 cycloalkanoyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C10 virtues Base, C6-C10 aryloxy group, C6-C10 aroyls, C6-C10 fragrant aminos, C6-C10 aryl C1-C6 alkoxies, C6-C10 virtues Base alkylamino, C5-C12 heteroaryls, C5-C12 heteroaryloxies, C5-C12 4-hetaroylpyrazols, C5-C12 heteroaryl amino, C5- C12 heteroaryl C1-C6 alkoxies, C5-C12 heteroaryl C1-C6 alkylaminos, C4-C12 heterocycle C1-C6 alkanoyls, C4- C12 Heterocyclylalkyls, C4-C12 heterocycle oxygroups, C4-C12 heterocyclylamino groups, C4-C12 heterocyclylacyls, C4-C12 heterocycles Base C1-C6 alkoxies, C4-C12 heterocycle C1-C6 alkylaminos, C4-C12 heterocycle C1-C6 alkanoyls, R5R4N-, -C(= O)NR4R5, -OC(=O)NR4R5, -OC(=O)OR4, -N(R4)C(=O)NR4R5, -N(R4)C(=O)OR5, -N(R4)C(=O)- R5, R4R5N-S(=O)t-, R4S(=O)t-, R4S(=O)tN(R5)-, R5R4N-C1-C6 alkyl, R4S(=O)t- C1-C6 alkane Base, R4R5N-C (=O)-C1-C6 alkyl, R5R4N-C1-C6 alkoxies, R4S(=O)t- C1-C6 alkoxies, R4R5N-C(=O)- C1-C6 alkoxies, C6-C10 aryl-(CH2)p-G-(CH2)m, C5-C12 heteroaryls-(CH2)p-G-(CH2)m-, C4-C12 Heterocycle-(CH2)p-G-(CH2)m, or C3-C10 naphthenic base-(CH2)p-G-(CH2)m, wherein G is O, S, NR6, S(= O), S(=O)2,C(=O), -C(=O)N(R4)-, -OC(=O)N(R4)-, -OC(=O)-, -N(R4)C(=O)N(R4)-, - (R4)N-S(=O)t-, -OS(=O)t, or-OS (=O)tN(R4)-;T is l or 2;P and m is each independently 0, l, 2,3 Or 4;Or wherein C6-C10 aryl-(CH2)p-G-(CH2)m, C5-C12 heteroaryls-(CH2)p-G-(CH2)m-, C4-C12 Heterocycle-(CH2)p-G-(CH2)m, or C3-C1 naphthenic base-(CH2)p-G-(CH2)mCan F be selected from by one or more, The substituent group of Cl, Br, I, alkyl, alkenyl, alkynyl, alkoxy or cyano replaces.
R2It is each independently H, C1-C20 alkyl, C1-C20 halogenated alkyls, C1-C20 alkyl acyls, C1-C20 hydroxyls Base alkanoyl, C1-C20 ohaloalkanoyls, C3-C10 naphthenic base, C3-C10 cycloalkanoyls, C2-C8 alkenyls, C2-C8 Alkenyl alkanoyl, C2-C8 alkynyls, C2-C8 alkynyl alkanoyls, C6-C10 aryl, C6-C10 aroyls, C5-C12 heteroaryls Base, C5-C12 4-hetaroylpyrazols, C4-C12 heterocycle alkanoyls, C4-C12 Heterocyclylalkyls, C4-C12 heterocyclylacyls, C4- C12 heterocycle C1-C6 alkanoyls, C5-C12 condensed-bicyclic bases, C5-C12 condense miscellaneous bicyclic group ,-C (=O) NR4R5, R4R5N-S(=O)t-, R4S(=O)t-, R5R4N-C1-C6 alkyl, R4S(=O)t- C1-C6 alkyl, R4R5N-C(=O)-C1-C6 Alkyl, C6-C10 aryl-(CH2)p-G-(CH2)m, C5-C12 heteroaryls-(CH2)p-G-(CH2)m, C4-C12 heterocycles- (CH2)p-G-(CH2)m, or C3-C10 naphthenic base-(CH2)p-G-(CH2)m, wherein G is O, S, NR8, S(=O), S(= O)2,C(=O), -C(=O)N(R4)-, -OC(=O)N(R4)-, -OC(=O)-, -(R4)N-S(=O)t-, -OS(=O)t-, Or-OS (=O)tN(R4)-;T is l or 2;P and m is each independently 0, l, 2,3 or 4;Or wherein C6-C10 aryl- (CH2)p-G-(CH2)m, C5-C12 heteroaryls-(CH2)p-G-(CH2)m, C4-C12 heterocycles-(CH2)p-G-(CH2)m-, Or C3-C10 naphthenic base-(CH2)p-G-(CH2)mCan by one or more be selected from F, Cl, Br, I, cyano, alkyl, Alkenyl, alkynyl, alkoxy, aryl, heteroaryl, carbocylic radical, the substituent group substitution of heterocycle.
Wherein each R6Can be identical or different, it is each independently H, R4R5NC(=O)-, R4OC(=O)-, R4C(= O)-, R4R5NS(=O)-, R4OS(=O)-, R4S(=O)-, R4R5NS(=O)2-, R4OS(=O)2-, R4S(=O)2-, C1-C3 Aliphatic, C1-C3 halogenated aliphatics, C1-C3 hydroxyl group aliphatics, C1-C3 amino aliphatic, C1-C3 alkoxy C 1-C3 fat Fat race, C1-C3 alkylamino C1-C3 aliphatic, C1-C3 alkylthio group C1-C3 aliphatic, C6-C10 aryl C1-C3 aliphatic, C5-C9 heteroaryl C1-C3 aliphatic, C4-C10 heterocycle C1-C3 aliphatic, C3-C10 naphthenic base C1-C3 aliphatic, C6- C10 aryloxy group C1-C3 aliphatic, C4-C10 heterocycle oxygroup C1-C3 aliphatic, C3-C10 cycloalkyl oxies C1-C3 fat Race, C6-C10 fragrant amino C1-C3 aliphatic, C4-C10 heterocyclylamino group C1-C3 aliphatic, C3-C10 cycloalkyl aminos C1- C3 aliphatic, C6-C10 aryl, C5-C10 heteroaryls, C4-C10 heterocycles or C3-C10 naphthenic base.
Wherein each R4And R5It independently is H, C1-C3 aliphatic, C1-C3 halogenated aliphatics, C1-C3 hydroxyl group aliphatics, C1-C3 amino aliphatic, C1-C3 alkoxy C 1-C3 aliphatic, C1-C3 alkylamino C1-C3 aliphatic, C1-C3 alkylthio groups C1-C3 aliphatic, C6-C10 aryl C1-C3 aliphatic, C5-C9 heteroaryl C1-C3 aliphatic, C4-C10 heterocycles C1-C3 Aliphatic, C3-C10 naphthenic base C1-C3 aliphatic, C6-C10 aryloxy group C1-C3 aliphatic, C4-C10 heterocycle oxygroups C1- C3 aliphatic, C3-C10 cycloalkyl oxy C1-C3 aliphatic, C6-C10 fragrant amino C1-C3 aliphatic, C4-C10 heterocycles Amino C1-C3 aliphatic, C3-C10 cycloalkyl amino C1-C3 aliphatic, C6-C10 aryl, C5-C10 heteroaryls, C4- C10 heterocycles or C3-C10 naphthenic base;Work as R4And R5It is connected on the same nitrogen-atoms, R4, R5It can be arbitrarily with nitrogen-atoms Form substituted or non-substituted 3-6 membered rings.
Above-mentioned R1, R2, R3, R4, R5, R6Group can appoint by deuterium, halogen, hydroxyl, methylol, carboxyl, acetyl Amino, alkyl（Such as methyl, ethyl, propyl）, alkoxy（Such as methoxyl group, ethyoxyl, tert-butoxy）, alkylamino, cycloalkanes Base, alkenyl, alkynyl, trifluoromethyl, trifluoroacetyl group, sulfydryl, halogen, nitro, amino, azido (- N3), Guanidine radicals, cyano, tertbutyloxycarbonyl (- Boc), carbonyl (- C=O), oxo (=O) is thio (=S), sulfonyl, virtue Base, heteroaryl, the substitution of one or more of heterocycle.
In some embodiments, compound of the present invention, wherein each R1, R3Can be identical or different, respectively solely It is on the spot H, D, F, Cl, Br, I, hydroxyl, amino, nitro, cyano, methyl, ethyl, propyl, isopropyl, Butyl, tertiary butyl, C5H11, C6H13, C8H17, trifluoromethyl, hydroxymethyl, amino methyl, methoxyl group, ethyoxyl, Tert-butoxy, methylamino, ethylamino, isopropylamino, 3- hydroxyl-propyls, acetyl group, trifluoroacetyl group, cyano-acetamide Base, methylamino acetyl group, propiono, iso-propionyl, 2- hydroxypropanoyls, 2- aminopropionyls, 2- chlorine propionos, 2- bromine propionos, valeryl, caproyl, heptanoyl group, methacrylyl, phenyl, benzoyl, p-nitrophenyl, To methyl benzoyl, fluoro benzoyl, p-benzoyl base, to methoxybenzoyl base, 2,4- dimethyl benzenes Formoxyl, azidobenzoyl, benzyl, p-chlorobenzyl, vinyl, acrylic, allyl, n-butene base, Isobutenyl, n-pentene base, isopentene group, cyclopropyl, ring propiono, ring valeryl, cyclohexanoyl, 3- pyridine first Acyl group, naphthalene, phenethyl imidazole radicals, pyridyl group, pyrrole radicals, oxazolyl, isoxazolyls, triazol radical, tetrazole Base, furyl, thienyl, thiazolyl, piperidyl, piperazinyl, indyl, carbazyl, benzofuranyl tetrahydrochysene furan It mutters base, THP trtrahydropyranyl, pyrimidine bases, purine bases ,-N (CH3)2,-C (C=O) NH-C1-C4 alkyl ,-OC (C=O)- NH-C1-C4 alkyl ,-OC (O=O) O-C1-C4 alkyl ,-NHC (=O) NH-C1-C4 alkyl ,-NHC (=O) O-C1-C4 alkyl, - NHC (=O)-C1-C4 alkyl, C1-C4 alkyl-NH-S (=O)2, C1-C4 alkyl S (=O)2, C1-C4 alkyl S (=O)2NH-, phenyl-(CH2)P-G-(CH2)m, difluorophenyl-(CH2)P-G-(CH2)m, thiazolyl-(CH2)p-G-(CH2)m-, Pyridyl group-(CH2)p-G-(CH2)m, phenylethyl, cyclohexyl-(CH2)p-G-(CH2)m, wherein G is O, S, S (= O), S (=O)2, C(=O);P and m is each independently 0,1,2 or 3;Or wherein C6-C10 aryl-(CH2)P-G- (CH2)mCan F, Cl, Br, I, methyl, ethyl, propyl, acetenyl, propinyl, fourth be selected from by one or more The substituent group of alkynyl, methoxyl group, ethyoxyl or cyano replaces;Or above-mentioned R1, R3It is welcome by D, F, Cl, Br, I, hydroxyl, methylol, carboxyl, acetylamino, alkyl（Such as methyl, ethyl, propyl）, alkoxy（Such as methoxyl group, ethoxy Base, tert-butoxy）, alkylamino, naphthenic base, alkenyl, alkynyl, trifluoromethyl, trifluoroacetyl group, sulfydryl, halogen, Nitro, amino, azido (- N3), guanidine radicals, cyano, tertbutyloxycarbonyl (- Boc), carbonyl (- C=O), oxo (= ), O thio (=S), sulfonyl, aryl, heteroaryl, the substitution of one or more of heterocycle.
Each R2Can be identical or different, it is each independently H, methyl, ethyl, propyl, isopropyl, butyl, uncle Butyl, C5H11, C6H13, C8H17, trifluoromethyl, hydroxymethyl, amino methyl, 3- hydroxyl-propyls, acetyl group, three Acetyl fluoride base, Cyanoacetyl, methylamino acetyl group, propiono, iso-propionyl, 2- hydroxypropanoyls, 2- amino Propiono, 2- chlorine propionos, 2- bromine propionos, valeryl, caproyl, heptanoyl group, methacrylyl, phenyl, benzene Formoxyl, p-nitrophenyl, to methyl benzoyl, fluoro benzoyl, p-benzoyl base, to methoxybenzene Formoxyl, 2,4- dimethylbenzoyls, azidobenzoyl, benzyl, p-chlorobenzyl, vinyl, acrylic, Allyl, n-butene base, isobutenyl, n-pentene base, isopentene group, cyclopropyl, ring propiono, ring valeryl, Cyclohexanoyl, 3- picolinoyls, naphthalene, phenethyl imidazole radicals, pyridyl group, pyrrole radicals, oxazolyl, isoxazolyls, Triazol radical, tetrazole base, furyl, pyranose, thienyl, thiazolyl, piperidyl, piperazinyl, indyl, Carbazyl, benzofuranyl tetrahydrofuran base, THP trtrahydropyranyl, pyrimidine bases, purine bases, pentose base, six carbon Glycosyl ,-(C=O) NH-C1-C4 alkyl, C1-C4 alkyl-NH-S (=O)2, C1-C4 alkyl S (=O)2, phenyl- (CH2)P-G-(CH2)m, difluorophenyl-(CH2)P-G-(CH2)m, thiazolyl-(CH2)p-G-(CH2)m, pyridyl group- (CH2)p-G-(CH2)m, phenylethyl, cyclohexyl-(CH2)p-G-(CH2)m, wherein G is O, S, S (=O), S (= O)2, C(=O);P and m is each independently 0,1,2 or 3;Or wherein C6-C10 aryl-(CH2)P-G-(CH2)mIt can be with F, Cl, Br, I, methyl, ethyl, propyl, acetenyl, propinyl, butynyl, methoxy are selected from by one or more The substituent group of base, ethyoxyl or cyano replaces;Or above-mentioned R2It is welcome by D, F, Cl, Br, I, hydroxyl, hydroxyl Base, methylol, carboxyl, acetylamino, C1-C6 alkyl（Such as methyl, ethyl, propyl）, C1-C6 alkoxies, C1-C6 alkane Amino, trifluoromethyl, trifluoroacetyl group, sulfydryl, nitro, amino, azido (- N3), guanidine radicals, cyano, tertiary fourth Oxygen carbonyl (- Boc), carbonyl (- C=O), oxo (=O), thio (=S), sulfonyl, one or more of phenyl takes Generation.
In other embodiments, compound of the present invention have the structure comprising following one or it is following it It is the tautomer of one structure, stereoisomer, racemic modification, the non-equal amount of mixture of enantiomter, geometric isomer, molten The solvate of agent compound, pharmaceutically acceptable salt or its salt, or prodrug：
。
One aspect of the present invention is related to pharmaceutical composition, including the compound of the present invention, or its stereoisomer, geometry Isomers, tautomer, nitrogen oxides, hydrate, solvate, metabolite, pharmaceutically acceptable salt or Their prodrug, or optional pharmaceutically acceptable carrier, excipient, diluent, adjuvant, medium, or they Combination.
One aspect of the present invention is related to preventing, handle, treat or mitigating patient caused by inflammation, immune system disorder etc. respectively The method of kind of disease, including use the pharmaceutically acceptable effective dose of the pharmaceutical composition of the compounds of this invention to patient into Row administration.
One aspect of the present invention is related to preventing, handle, treat or mitigating patient caused by inflammation, immune system disorder etc. respectively The method of kind disease, including the pharmaceutically acceptable effective dose of the compounds of this invention is used to be administered patient.
Another aspect of the present invention is related to the compound of the present invention and is used to prepare for preventing, handling, treat or mitigating patient The purposes of the drug of various diseases caused by inflammation, immune system disorder etc..
Another aspect of the present invention, which is related to being used to prepare using a kind of pharmaceutical composition comprising the compound of the present invention, to be used for The purposes for preventing, handling, treating or mitigate patient's drug of various diseases caused by inflammation, immune system disorder etc..
On the other hand, preventing or treating to move using the compounds of this invention or its pharmaceutical composition the present invention relates to a kind of The method for application of object or the human body various diseases caused by inflammation, immune system disorder etc., the purposes include using the present invention's Pharmaceutically acceptable effective therapeutic dose of compound or its pharmaceutical composition is administered human body or animal.
Some of embodiments are the diseases of the present invention caused by inflammation, immune system disorder etc..The disease Disease selects kidney region fibrosis, glomerulosclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosiss, myocardial fibrosis, skin fiber Change, postoperative intestinal adhesion, benign prostatauxe disease, skeletal muscle fibre, chorionitis, multiple sclerosis, pancreatic fibrosis, Hepatic sclerosis, muscle tumor, nerve fibre onch- interstitial fibrosis, diabetic nephropathy, Alzheimer disease, vascular fibrosis, slurries Property inflammation, fibrinous inflammation, suppurative inflammation, hemorrhagic inflammation, gangrenous inflammation, catarrhal inflammation, tuberculosis, syphilis, leprosy, lymph granulation Swollen, allergy, rheumatoid arthritis, rheumatoid heart disease, AIDS, delayed immunological disease, cell toxicant type immunological disease, nerve Degenerative disease etc..
Some of embodiments are that drug of the present invention is for treating by tumor necrosis factor (TNF-a), Bai Jie The factors such as element-β, lipopolysaccharides (LPS), oxidant, radioactive ray, ultraviolet light, virus and its metabolite activation NF- κ Factor Bs cause Immune dysfunction diseases.
Content noted earlier only outlines certain aspects of the invention, but is not limited to these aspects.These aspect and its The content of his aspect will make more specific complete description below.
Definition and general terms
The present invention will be corresponding to the content determining materialization document list in detail, embodiment is all accompanied by structural formula With the explanation of chemical formula.The present invention, which has, expectedly covers all choices, variant and coordinate, these possible pictures Existing invention field is included in defined in claim like that.Those skilled in the art will identify many similar or equivalent In method described herein and substance, these can be applied to the practice of the present invention.The present invention be limited to absolutely not method and The description of substance.There are many documents and similar substance to distinguish or contradict with the present patent application, including but not limited to The definition of term, the usage of term, the technology of description, or the range that is controlled as the present patent application.
The present invention will apply defined below unless other aspects show.Purpose according to the present invention, chemical element is according to member Plain periodic table, CAS versions and chemicals handbook, 75,thEd, 1994 define.In addition, organic chemistry General Principle is shown in “Organic Chemistry,” Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry,” by Michael B. Smith and Jerry March, John. Wiley&Sons, New York:2007, therefore all contents have all merged bibliography.
As described in the invention, the compound of the present invention can optionally be replaced by one or more substituent groups, Such as general formula compound above, or as example special inside embodiment, subclass, and one kindization that the present invention is included Close object.It should be appreciated that this term can exchange use to " optionally replacing " this term with " substituted or non-substituted ".It is general and Speech, term " optionally " whether it is before the term " replaced ", indicate that one or more of given structure hydrogen is former Son is replaced by specific substituent group.Unless other aspects show, one optional substituent group can there are one substituent groups in base The each commutable position of group is replaced.When more than one position can be by one for specific group in given structural formula Or multiple substituent groups are replaced, then substituent group can replace at various locations identical or differently.The wherein substituent group It can be, but be not limited to, halogenated alkyl, hydroxyl, amino, halogen, cyano, aryl, heteroaryl, alkoxy, Alkylamino, alkylthio group, alkyl, alkenyl, alkynyl, heterocycle, sulfydryl, nitro, aryloxy group, heteroaryloxy, oxo (=O), carboxyl, the alkoxy of hydroxyl substitution, the alkyl-C (=O)-of hydroxyl substitution, alkyl-C (=O)-, alkyl-S (= O)-, alkyl-S (=O)2, the alkyl-S (=O)-of hydroxyl substitution, the alkyl-S (=O) of hydroxyl substitution2, Carboxyalkoxy etc. Deng.
Terminology used in the present invention " aliphatic " or " aliphatic group " indicate straight chain（It is i.e. non-branched）Or branch, it takes Generation or non-substituted fully saturated or containing one or more degrees of unsaturation hydrocarbon chain.Unless otherwise detailed instructions, fatty group 1-20 carbon atom is contained in group, and some of embodiments are that aliphatic group contains 1-10 carbon atom, and other is real Applying example is, aliphatic group contains 1-8 carbon atom, and other embodiment is that it is former that aliphatic group contains 1-6 carbon Son, other embodiment are that aliphatic group contains 1-4 carbon atom, and other embodiment is aliphatic group Contain 1-3 carbon atom.Suitable aliphatic group is including but not limited to linear chain or branched chain is substituted or non-substituted Alkyl, alkenyl or alkynyl, such as methyl, ethyl, propyl, isopropyl, butyl, tertiary butyl, hexyl, isobutyl group are secondary Butyl, vinyl etc..
Terminology used in the present invention " halogenated aliphatic " indicates aliphatic group by one or more identical or different halogen Atom is replaced, wherein aliphatic group have meaning as described in the present invention, halogen atom, that is, fluorine, chlorine, bromine or iodine, in this way Example including but not limited to trifluoromethyl, trifluoroethyl, chloromethyl, 2- chlorovinyls etc..
Terminology used in the present invention " hydroxyl group aliphatic " indicates that aliphatic group is replaced by one or more hydroxyl groups, Wherein aliphatic group has meaning as described in the present invention, and such example is including but not limited to ethoxy, 2- hydroxyls Base propyl, methylol etc..
Terminology used in the present invention " amino aliphatic " indicates that aliphatic group is replaced by one or more amino groups, Wherein aliphatic group has meaning as described in the present invention, and such example is including but not limited to amino methyl, 2- Amino-ethyl, 2- amino isopropyls etc..
Terminology used in the present invention " alkyl " includes 1-20 carbon atom, or 1-10 carbon atom, or 1-6 carbon original Son, or 1-4 carbon atom, or 1-3 carbon atom saturated straight chain or branch univalence hydrocarbyl, wherein alkyl can independently appoint Selection of land is replaced by one or more substituent groups described in the invention.The further example of alkyl includes, but and unlimited In methyl (Me ,-CH3), ethyl (Et ,-CH2CH3), n-propyl (n-Pr ,-CH2CH2CH3), isopropyl (i-Pr ,- CH(CH3)2), normal-butyl (n-Bu ,-CH2CH2CH2CH3), isobutyl group (i-Bu ,-CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tertiary butyl (t-Bu ,-C (CH3)3), n-pentyl (- CH2CH2CH2CH2CH3), 2- amyls (- CH (CH3)CH2CH2CH3), 3- amyls (- CH (CH2CH3)2), 2- methyl -2- butyl (- C (CH3)2CH2CH3), 3- methyl -2- fourths Base (- CH (CH3)CH(CH3)2), 3- methyl-1s-butyl (- CH2CH2CH(CH3)2), 2-methyl-1-butene base (- CH2CH(CH3) CH2CH3), n-hexyl (- CH2CH2CH2CH2CH2CH3), 2- hexyls (- CH (CH3)CH2CH2CH2CH3), 3- hexyls (- CH (CH2CH3)(CH2CH2CH3)), 2- methyl -2- amyls (- C (CH3)2CH2CH2CH3), 3- methyl -2- amyls (- CH (CH3)CH (CH3)CH2CH3), 4- methyl -2- amyls (- CH (CH3)CH2CH(CH3)2), 3- methyl -3- amyls (- C (CH3) (CH2CH3)2), 2- methyl -3- amyls (- CH (CH2CH3)CH(CH3)2), 2,3- dimethyl -2- butyl (- C (CH3)2CH (CH3)2), 3,3- dimethyl -2- butyl (- CH (CH3)C(CH3)3), n-heptyl, n-octyl, etc..Term " alkyl " and Its prefix " alkane " uses here, all includes the saturated carbon chains of straight chain and branch.
Term " alkenyl " indicates 2-12 carbon atom, or 2-8 carbon atom, or 2-6 carbon atom, or 2-4 carbon original The monovalent hydrocarbon of sub- linear chain or branched chain, wherein at least one position are undersaturated condition, i.e., a C-C is sp2Double bond, The group of alkenyl groups can be replaced by one or more substituent groups described in the invention individually optionally, including group Have negation " just " or " E ∥ Z " positioning, wherein specific example is including but not limited to vinyl (- CH=CH2), alkene Propyl (- CH2CH=CH2), etc..
Term " alkynyl " indicates 2-12 carbon atom, or 2-8 carbon atom, or 2-6 carbon atom, or 2-4 carbon original The monovalent hydrocarbon of sub- linear chain or branched chain, wherein at least one position are undersaturated condition, i.e., a C-C is tri- keys of sp, wherein Alkynyl group can be replaced by one or more substituent groups described in the invention individually optionally, and specific example includes, But it is not limited to, acetenyl (three CH of-C), propargyl (- CH2Tri- CH of C), etc..
Term " alkyl of hydroxyl substitution " indicates that alkyl group is replaced by one or more hydroxyl groups, wherein alkyl Group has meaning of the present invention.Such example includes, but is not limited to methylol, ethoxy, l, 2- dihydroxies Base ethyl etc..
Term " carbocyclic ring ", " carbocylic radical ", " naphthenic base " refer to monovalence or multivalence, non-aromatic, saturation or part insatiable hunger And ring, and do not include hetero atom, two rings or tricyclic of monocycle or 7-12 carbon atom including 3-12 carbon atom.Tool The bicyclic carbocyclic ring of 7-12 atom can be two rings [4.5], [5.5], [5.6] or [6.6] system, while have 9 or 10 The bicyclic carbocyclic ring of atom can be two rings [5.6] or [6.6] system.Suitable cyclic aliphatic group including but not limited to, Naphthenic base, cycloalkenyl group and cycloalkynyl radical.The example of cyclic aliphatic group further comprises, but is not limited to, cyclopropyl, ring Butyl, cyclopenta, 1- cyclopenta -1- alkenyls, 1- cyclopenta -2- alkenyls, 1- cyclopenta -3- alkenyls, cyclohexyl, 1- rings Hexyl -1- alkenyls, 1- cyclohexyl -2- alkenyls, 1- cyclohexyl -3- alkenyls, cyclohexadienyl, suberyl, cyclooctyl, ring Nonyl, cyclodecyl, ring undecyl, cyclo-dodecyl, adamantyl etc..And " carbocyclic ring ", " carbocylic radical ", " naphthenic base " can be substituted or non-substituted, and wherein substituent group can be, but be not limited to, halogenated alkyl, hydroxyl, Amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, heterocycle, mercapto Base, nitro, aryloxy group, the alkoxy of hydroxyl substitution, the alkyl-C (=O)-of hydroxyl substitution, alkyl-C (=O)-, alkyl- S (=O)-, alkyl-S (=O)2, the alkyl-S (=O)-of hydroxyl substitution, the alkyl-S (=O) of hydroxyl substitution2, carboxyl alcoxyl Base etc..
Term " cycloalkyl oxy " or " carbocylic radical oxygroup " include the naphthenic base optionally replaced or carbocylic radical, such as present invention It is defined, it is connected on oxygen atom, and be connected with remaining molecule by oxygen atom, such example includes, but not It is limited to cyclopropyl oxygroup, cyclopentyloxy, cyclohexyl oxygroup, the cyclopropyl oxygroup etc. of hydroxyl substitution.
Term " cycloalkyl amino " indicates that amino group is replaced by one or two group of naphthene base, wherein naphthenic base With meaning as described in the present invention, such example is including but not limited to cyclopropylamino, clopentylamino, ring Hexylamino, the cyclopropylamino of hydroxyl substitution, dicyclohexyl amino, Bicyclopropyl amino etc..
Term " cycloalkyl oxy aliphatic " indicates that aliphatic group is replaced by one or more cycloalkyl oxy groups, Wherein aliphatic group and cycloalkyl oxy group have meaning as described in the present invention, and such example includes, but not It is limited to cyclopropyl oxygroup methyl, cyclopropyl oxygroup ethyl, cyclopentyloxymethyl, cyclopentyloxy ethyl, cyclohexyl oxygen Base ethyl, halogenated cyclopropyl oxygroup ethyl etc..
Term " cycloalkyl amino aliphatic " indicates that aliphatic group is replaced by one or more cycloalkylamino groups, Wherein aliphatic group and cycloalkylamino group have meaning as described in the present invention, and such example includes, but not It is limited to Cyclopropylaminomethyl, cyclopropylamino hexyl, clopentylamino methyl, clopentylamino ethyl, cyclohexyl ammonia Base ethyl, halogenated cyclopropyl amino-ethyl etc..
Term " naphthenic base aliphatic " or " carbocylic radical aliphatic " indicate that aliphatic group can be by one or more naphthenic base Group or carbocylic radical group are replaced, wherein naphthenic base, or carbocylic radical and aliphatic group have and contain as described in the present invention Justice, such example is including but not limited to Cvclopropvlmethvl, cyclopropylethyl, Cyclopropylpropyl, cyclopentyl-methyl, Cyclohexyl-ethyl etc..
Term " heterocycle ", " heterocycle ", " heteroalicyclic " or " heterocycle " are used interchangeably here, all refer to list Ring, bicyclic, or three-ring system, one or more atoms are replaced by hetero atom individually optionally in beanstalk middle ring, and ring can be with It is fully saturated or comprising one or more degrees of unsaturation, but definitely not aromatic, is only connected to there are one tie point Other molecules get on.One or more ring hydrogen atoms are individually optionally by one or more substituent groups described in the invention Replaced.Some of embodiments are that " heterocycle " " heterocycle " " heteroalicyclic " or " heterocycle " group are the lists of 3-7 membered rings Ring（1-6 carbon atom and be N, O, P, the 1-3 hetero atom of S, in this S or P optionally by one or more oxygen atom institutes Substitution is obtained as SO, SO2, PO, PO2Group, when the ring is a three-membered ring, only one of which hetero atom), Or 7-10 members is bicyclic（4-9 carbon atom and be N, O, P, the 1-3 hetero atom of S, in this S or P optionally by one or Multiple oxygen atoms replace to obtain as SO, SO2, PO, PO2Group）.
Heterocycle can be carbon-based or heteroatom group." heterocycle " equally also includes heterocyclic group and saturation or part insatiable hunger With ring or heterocycle and close be formed by group.The example of heterocycle is including but not limited to, pyrrolidinyl, tetrahydrofuran base, Dihydrofuryl, tetrahydro-thienyl, THP trtrahydropyranyl, dihydro pyranyl, tetrahydro thiapyran base, piperidyl, morpholinyl, Thio-morpholinyl, thioalkyls, piperazinyl, high piperazine base, azelidinyl, oxetanylmethoxy, thietanyl, Piperidyl, homopiperidinyl, glycidyl, azacycloheptyl, oxetane, thiocycloheptyl, 4- methoxyl groups-piperazine Pyridine -1- bases, l, 2,3,6- tetrahydropyridine -1- bases, oxygen azatropylidene base, diazepine base, sulphur azatropylidene base, pyrroles Quinoline -1- bases, 2- pyrrolinyls, 3- pyrrolinyls, indolinyl, dihydro pyranyl, THP trtrahydropyranyl, dioxane Hexyl, l, 3- dioxymyls, pyrazolinyl, dithianyl, dithienyl group, dihydrothiophene, pyrazolidinyl imidazoles Quinoline base, imidazolidinyl, l, 2,3,4- tetrahydro isoquinolyls, l, 2,6- thiadiazine alkane l, 1- dioxy -2- bases, 4- hydroxyls Base-l, 4- azepine phosphine 4- oxide -1- bases, 2- hydroxyls -1-（Piperazine -1- bases）Ethyl ketone -4- bases, 2- hydroxyls -1-（5, 6- Dihydro-l, 2,4- triazine-l（4H）Base）Ethyl ketone -4- bases, 5,6- dihydros -4H- 1,2,4- oxadiazine -4- bases, 2- hydroxyls Base -1-（5,6- dihydropyridines-l（2H）Base）Ethyl ketone -4- bases, 3- azabicyclos [3.1.0] hexyl, 3- azabicyclos [4.1.0] heptyl, azabicyclo [2.2.2] hexyl, 2- methyl -5,6,7,8- tetrahydrochysenes-[1.2.4] triazole [1,5-c] are phonetic Pyridine -6- bases, 4,5,6,7 1 tetrahydrochysene isoxazoles [4,3-c] pyridine -5- bases, 3HIndyl 2- oxygen -5- azabicyclos [2.2.1] heptane -5- bases, 2- oxygen -5- azabicyclos [2.2.2] octane -5- bases, quinazinyl and N- pyridyl ureas.Heterocycle The example of group further includes l, and two carbon atoms are replaced by oxygen atom as phonetic on 1- dioxidothiomorpholinyls, and its middle ring Pyridine diketo.And the heterocycle can be substituted or non-substituted, and wherein substituent group can be, but be not limited to, halogen Substituted alkyl, oxo (=O), hydroxyl, amino, halogen, cyano, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, Alkynyl, heterocycle, sulfydryl, nitro, aryloxy group, the alkoxy of hydroxyl substitution, the alkyl-C (=O)-of hydroxyl substitution, alkane Base-C (=O)-, alkyl-S (=O)-, alkyl-S (=O)2Alkyl-the S (=O)-of hydroxyl substitution, the alkyl-S of hydroxyl substitution (=O)2, Carboxyalkoxy etc..
Term " heterocycle aliphatic " indicates the aliphatic group of heterocycle substitution, wherein heterocycle and aliphatic group With meaning as described in the present invention, such example is including but not limited to pyrroles's -2- methyl, piperidines -2- ethyls, Piperazine -2- ethyls, piperidines -2- methyl etc..
Term " heterocycle oxygroup " includes that the heterocycle optionally replaced is connected to oxygen atom as defined herein On, wherein oxygen atom is connected with the rest part of molecule, and such example is including but not limited to pyrroles's -2- oxygroups, pyrrole Cough up -3- oxygroups, piperidines -2- oxygroups, piperidines -3- oxygroups, piperazine -2- oxygroups, piperidines -4- oxygroups etc..
Term " heterocyclylamino group " indicates that amino group is replaced by one or two heterocyclyl groups, wherein nitrogen-atoms It is connected with the rest part of molecule, and heterocycle has meaning as described in the present invention, such example includes, but simultaneously It is not limited to pyrroles's -2- amino, pyrroles's -3- amino, piperidines -2- amino, piperidines -3- amino, piperidines -4- amino, piperazine - 2- amino, two pyrroles's -2- amino etc..
Term " heterocycle oxygroup aliphatic " indicates that aliphatic group is replaced by one or more heterocycle oxygroup groups, Wherein aliphatic group and heterocycle oxygroup group have meaning as described in the present invention, and such example includes, but not It is limited to pyrroles's-2- oxygroup methyl, piperazine-3- oxygroup ethyls, piperazine-2- oxygroup ethyls, morpholine -2-oxygroup methyl, piperidines- 2- oxygroup ethyls etc..Term " heterocyclylamino group aliphatic " indicates aliphatic group by one or more heterocyclylamino group group institutes Replace, wherein aliphatic group and heterocyclylamino group group include with meaning as described in the present invention, such example, But pyrroles's -2- amino methyls are not limited to, piperazine -3- amino-ethyls, piperazine -2- amino-ethyls, piperidines -2- amino-ethyls, Morpholine -2-amino methyl etc..
Term " hetero atom " indicates one or more O, S, N, P and Se, includes the shape of any oxidation state of N, S and P Formula;The form of primary, secondary, tertiary amine and quaternary ammonium salt;Or the substituted form of hydrogen in heterocycle on nitrogen-atoms, such as, N (as 3,4- dihydros -2HN in pyrrole radicals), NH (as the NH in pyrrolidinyl) or NR are (in the pyrrolidinyl replaced as N- NR)。
Term " halogen " refers to F, Cl, Br or I.
Contain one or more degrees of unsaturation in " undersaturated " the expression part of term as used in the present invention.
Term " alkoxy " used in the present invention, is related to alkyl, as defined in the present invention, passes through oxygen original Son（" alkoxy "）It being connected in main carbochain, such example is including but not limited to methoxyl group, ethyoxyl, and third Oxygroup, butoxy etc..And the alkoxy can be substituted or non-substituted, and wherein substituent group can be, but and unlimited In, hydroxyl, amino, halogen, cyano, alkoxy, alkyl, alkenyl, alkynyl, sulfydryl, nitro etc..
Term " alkoxy of hydroxyl substitution " or " hydroxy alkoxy base " indicate alkoxy base by one or more hydroxyl bases Group is replaced, and wherein alkoxy has meaning as described in the present invention, and such example is including but not limited to hydroxyl methoxy Base, 2- hydroxyl-oxethyls, 2- hydroxy propyloxy groups, 2- hydroxyl isopropyl oxygen etc..
Term " aminoalkoxy " indicates that alkoxy base is replaced by one or more amino groups, wherein alkoxy With meaning as described in the present invention, such example is including but not limited to ammonia methoxyl group, 2- amino ethoxies, 2- Amino propoxyl group, 2- amino isopropoxies etc..
Term " halogenated alkyl " " halogenated alkenyl " and " halogenated alkoxy " indicate alkyl, and alkenyl or alkoxy can be by one The case where a or multiple halogen atoms are replaced, such example is including but not limited to trifluoromethyl, the chloro- ethylene of 2- Base, trifluoromethoxy etc..
Term " aryl " indicates monocycle altogether containing 6-14 membered rings, bicyclic, and tricyclic carbocyclic ring system, wherein, until Few member ring systems are aromatic, and wherein each member ring systems includes 3-7 membered rings, and only there are one attachment point and molecules Rest part is connected.Term " aryl " can be exchanged with term " aromatic rings " and be used, if aromatic rings may include phenyl, naphthalene And anthracene.And the aryl can be substituted or non-substituted, and wherein substituent group can be, but be not limited to, alkyl halide Base, hydroxyl, amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, Heterocycle, sulfydryl, nitro, aryloxy group, the alkoxy of hydroxyl substitution, the alkyl-C (=O)-of hydroxyl substitution, alkyl-C (= O)-, alkyl-S (=O)-, alkyl-S (=O)2, the alkyl-S (=O)-of hydroxyl substitution, alkyl-the S (=O of hydroxyl substitution )2, Carboxyalkoxy etc..
Term " difluorophenyl " indicates that phenyl group is replaced by one or more fluorine atoms.
Term " aromatic yl aliphat " indicates that aliphatic group is replaced by one or more aryl groups, wherein aliphatic Group and aryl group have meaning as described in the present invention, and such example is including but not limited to phenethyl, benzene first Base, to methylphenylethyl, styryl etc..
Term " aryloxy group " or " aryloxy " include that the aryl optionally replaced is connected to as defined herein On oxygen atom, and it is connected with molecule rest part by oxygen atom, wherein aryl group has meaning as described in the present invention, Such example is including but not limited to phenoxy group, toloxyl, ethylbenzene oxygroup etc..
Term " fragrant amino " indicates that amino group is replaced by one or two aryl group, and wherein aryl has such as this The invention meaning, such example is including but not limited to phenyl amino, p-fluorophenyl amino, diphenyl amino, Xylyl amino, di-p-tolyl amino etc..
Term " aryloxy group aliphatic " indicates that aliphatic group is replaced by one or more aryloxy groups, wherein virtue Oxygroup and aliphatic group have a meaning as described in the present invention, such example including but not limited to phenoxymethyl, Phenoxyethyl, tolyloxyethyl, phenoxy propyl etc..
Term " heteroaryloxy aliphatic " indicates that aliphatic group is replaced by one or more heteroaryloxy groups, Middle heteroaryloxy and aliphatic group have meaning as described in the present invention, and such example is including but not limited to furans Oxygroup methyl, 2-pyrimidinyl oxy ethyl etc..
Term " fragrant amino aliphatic " indicates that aliphatic group is replaced by one or more fragrant amino groups, Middle fragrant amino and aliphatic group have meaning as described in the present invention, and such example is including but not limited to phenylamino Methyl, phenylaminoethyl, toluidino ethyl, phenylamino propyl, phenylamino allyl etc..
Term " alkoxy aryl " indicates that alkoxy base is replaced by one or more aryl, wherein aryl and alcoxyl Base has meaning of the present invention, and for such example including but not limited to Phenylmethoxy, phenyl ethoxy is right Methylphenylmethoxy, phenyl-propoxy etc..And the aryl can be substituted or non-substituted, and wherein substituent group can be with It is, but is not limited to, halogenated alkyl, hydroxyl, amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkane ammonia Base, alkyl, alkenyl, alkynyl, heterocycle, sulfydryl, nitro, aryloxy group, the alkoxy of hydroxyl substitution, hydroxyl substitution Alkyl-C (=O)-, alkyl-C (=O)-, alkyl-S (=O)-, alkyl-S (=O)2, the alkyl-S (=O)-of hydroxyl substitution, Alkyl-the S (=O) of hydroxyl substitution2, Carboxyalkoxy etc..
Term " aryl alkane amino " indicate alkylamino radicals replaced by one or more aryl groups, wherein aryl and Alkoxy has meaning of the present invention, and such example is including but not limited to phenyl methylamino, phenylethylamino, Phenylpropylamino, p-methylphenyl methylamino etc..
Term " heteroaryl " can be used alone or as most of " heteroaryl alkyl " or " heteroarylalkoxy ", Indicate the monocycle altogether containing 5-14 membered rings, it is bicyclic, and three-ring system, wherein at least one member ring systems are aromatic, and At least one member ring systems include one or more hetero atoms, and wherein each member ring systems includes 3-7 membered rings, and only there are one attached Point with molecule rest part to be connected.Term " heteroaryl " can be exchanged with term " heteroaromatic " or " heteroaromatics " to be made With.And the heteroaryl can be substituted or non-substituted, and wherein substituent group can be, but be not limited to, alkyl halide Base, hydroxyl, amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, Heterocycle, sulfydryl, nitro, aryloxy group, the alkoxy of hydroxyl substitution, the alkyl-C (=O)-of hydroxyl substitution, alkyl-C (= O)-, alkyl-S (=O)-, alkyl-S (=O)2, the alkyl-S (=O)-of hydroxyl substitution, alkyl-the S (=O of hydroxyl substitution )2, Carboxyalkoxy etc..
Other embodiment is that heteroaromatic includes monocycle below, but is not limited to these monocycles：2- furyls, 3- furyls, TMSIM N imidazole base, 2- imidazole radicals, 4- imidazole radicals, 5- imidazole radicals, 3- isoxazolyls, 4- isoxazolyls, 5- Isoxazolyl, 2- oxazolyls, 4- oxazolyls, 5- oxazolyls, 4- methyl-isoxazole -5- bases, N- pyrrole radicals, 2- pyrroles Base, 3- pyrrole radicals, 2- pyridyl groups, 3- pyridyl groups, 4- pyridyl groups, 2- pyrimidine radicals, 4- pyrimidine radicals, pyrimidine -5- bases are rattled away Piperazine base（Such as 3- pyridazinyls）, 2- thiazolyls, 4- thiazolyls, 5- thiazolyls, tetrazole radical（Such as 5- tetrazole radicals）, triazolyl（Such as 2- triazolyls and 5- triazolyls）, 2- thienyls, 3- thienyls, pyrazolyl（Such as 2- pyrazolyls）, isothiazolyl, l, 2, 3- oxadiazolyls, l, 2,5- oxadiazolyls, l, 2,4- oxadiazolyls, l, 2,3- triazolyls, l, 2,3- are thio Di azoly, l, 3,4- thio biphosphole bases, l, 2,5- thio biphosphole bases, l, 3,4- thiadiazoles -2- bases, pyrazinyl, Pyrazine -2- bases, l, 3,5- triazine radicals, benzo [d] thiazol-2-yl, imidazo [1,5-a] pyridine -6- bases;Also include It is below bicyclic, but it is bicyclic to be not limited to these：Benzimidazolyl, benzofuranyl, benzothienyl, benzothiazole Base, indyl（Such as 2- indyls）, purine radicals, quinolyl（Such as 2- quinolyls, 3- quinolyls, 4- quinolyls）, and it is different Quinolyl（Such as 1- isoquinolyls, 3- isoquinolyls or 4- isoquinolyls）.
Term " heteroaryl oxygroup " includes that the heteroaryl optionally replaced is connected to oxygen atom as defined herein On, and be connected with molecule rest part by oxygen atom, wherein heteroaryl groups have meaning as described in the present invention, this The example of sample is including but not limited to pyridine -2- oxygroups, thiazole -2- oxygroups, imidazoles -2- oxygroups, pyrimidine -2- oxygroups etc..
Term " Carboxyalkoxy " indicates that alkoxy base is replaced by one or more carboxylic groups, wherein alkoxy There is meaning as described in the present invention with carboxylic group, such example is including but not limited to Carboxvmethoxv, carboxyl Ethyoxyl etc..
Term " alkylthio group " includes that the alkyl of Cl-C10 linear chain or branched chains is connected on the sulphur atom of divalent.It is some of real Applying example is, alkylthio group is the C1-C3 alkylthio groups of lower level, and such example is including but not limited to methyl mercapto（CH3S-）. Term " halogenated alkylthio " includes that the halogenated alkyl of Cl-C10 is connected on bivalent sulfur atom.Some of embodiments are, halogenated Alkylthio group is the C1-C3 halogenated alkylthios of lower level, and such example is including but not limited to trifluoromethylthio.
Term " alkyl amino ", or " alkylamino ", including " N- alkyl aminos " and " N, N- dialkyl amido ", wherein Amine groups separately drive generation by one or two alkyl group.Some of embodiments are, alkyl amino be one or Two C1-C6 alkyl are connected to the alkylamino group of the lower level on nitrogen-atoms.Other embodiment is alkyl amino It is the alkylamino group of the lower level of C1-C3.Suitable alkylamino group can be alkyl monosubstituted amino or dialkyl amido, Such example is including but not limited to, N- methylaminos, N- ethylaminos, N, N- dimethylaminos, N, N- lignocaines Etc..
Term " heteroaryl amino " indicates that amine groups are replaced by one or two heteroaryl, and wherein heteroaryl has this The invention meaning, such example is including but not limited to N- thienyl amino etc..Some of embodiments are, miscellaneous Hetero-aromatic ring on arylamino can be further substituted.
Term " heteroaryl aliphatic " indicates that aliphatic group is replaced by one or more heteroaryls, wherein heteroaryl There is meaning of the present invention with aliphatic group, such example is including but not limited to thiophene -2- acrylic, pyrrole Pyridine -4- ethyls, imidazoles -2- methyl, furans -2- ethyls, indoles -3- methyl etc..
Term " heteroaryl alkyl " indicates that alkyl group is replaced by one or more heteroaryls, wherein heteroaryl and alkane There is base group meaning of the present invention, such example to include but be not limited to imidazoles -2- methyl, furans -2- second Base, indoles -3- methyl etc..
Term " heteroarylalkylamino " includes that the heteroarylalkyl group containing nitrogen-atoms is connected to other by nitrogen-atoms On group, wherein heteroaryl alkyl has meaning as described in the present invention, and such example is including but not limited to pyridine- 2- base methylaminos, thiazol-2-yl ethylamino, imidazoles -2- base ethylaminos, the third amino of pyrimidine -2-base, pyrimidine -2-base first ammonia Base etc..
Term " heteroarylalkoxy " includes that the heteroarylalkyl group containing oxygen atom is connected to other by oxygen atom On group, wherein heteroaryl alkyl has meaning as described in the present invention, and such example is including but not limited to pyridine- 2- ylmethoxies, thiazol-2-yl ethyoxyl, imidazoles -2- base oxethyls, pyrimidine -2-base propoxyl group, pyrimidine -2-base first ammonia Base.
Term " condensed-bicyclic ", " condensed ring ", " condensed-bicyclic base ", " condensed ring radical " indicate saturated or unsaturated condensed ring System is related to the bicyclic system of non-aromatic.Such system can include independent or conjugation undersaturated condition, but Its nuclear structure does not include aromatic rings or heteroaromatic（But aromatic series can be as substituent group thereon）.It is every in condensed-bicyclic One ring is either carbocyclic ring or is heteroalicyclic, and such example is including but not limited to, hexahydro furyl simultaneously [3,2- B] furans, 2,3,3a, 4,7,6- hexahydros -1HIndenes, 7- azabicyclos [2.3.0] heptane, condensed-bicyclic [3.3.0] Octane, condensed-bicyclic [3.1.0] hexane, l, 2,3,4,4a, 5,8,8a- octahydro naphthalenes, these are included in condensed Within bicyclic system.And the condensed-bicyclic base can be substituted or non-substituted, and wherein substituent group can be, but simultaneously It is not limited to, halogenated alkyl, oxo (=O), hydroxyl, amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkane Amino, alkyl, alkenyl, alkynyl, heterocycle, sulfydryl, nitro, aryloxy group, the alkoxy of hydroxyl substitution, hydroxyl take Alkyl-the C (=O)-in generation, alkyl-C (=O)-, alkyl-S (=O)-, alkyl-S (=O)2, hydroxyl substitution alkyl-S (= O)-, the alkyl-S (=O) of hydroxyl substitution2, Carboxyalkoxy etc..
Term " condensing miscellaneous bicyclic group " indicates saturated or unsaturated fused ring system, is related to the bicyclic body of non-aromatic System.Such system can include independent or conjugation undersaturated condition, but its nuclear structure does not include aromatic rings or virtue is miscellaneous Ring（But aromatic series can be as substituent group thereon）.And at least one member ring systems include one or more hetero atoms, wherein Each member ring systems include 3-7 membered rings, that is, include 1-6 carbon atom and be N, O, P, the 1-3 hetero atom of S, in this S Or P optionally is replaced to obtain as SO, SO by one or more oxygen atoms2, PO, PO2Group, such example includes, But it is not limited to hexahydro furyl simultaneously [3,2-b] furans, 7- azabicyclos [2.3.0] heptane etc..And it is described condensed miscellaneous bicyclic Base can be substituted or non-substituted, and wherein substituent group can be, but be not limited to, halogenated alkyl, oxo (=O), hydroxyl Base, amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, heterocycle, Sulfydryl, nitro, aryloxy group, the alkoxy of hydroxyl substitution, the alkyl-C (=O)-of hydroxyl substitution, alkyl-C (=O)-, alkane Base-S (=O)-, alkyl-S (=O)2, the alkyl-S (=O)-of hydroxyl substitution, the alkyl-S (=O) of hydroxyl substitution2, carboxyl Alkoxy etc..
Term " condensed-bicyclic base aliphatic " indicates that aliphatic group is replaced by one or more condensed-bicyclic base groups, Wherein aliphatic group and condensed-bicyclic base group have meaning as described in the present invention, and such example includes, but not It is limited to l, 2,3,4,4a, 5,8,8a- octahydro naphtylethyl groups, l, 2,3,4,4a, 5,8,8a- octahydro naphthalenes Methyl, l, 2,3,4,4a, 5,8,8a- octahydro naphthylpropyls, condensed-bicyclic [3.3.0] octane ylmethyl condense Bicyclic [3.1.0] hexyl ethyl etc..
Term " condensing miscellaneous bicyclic group aliphatic " indicates that aliphatic group condenses miscellaneous bicyclic group group institute by one or more Replace, wherein aliphatic group and condensed miscellaneous bicyclic group group include with meaning as described in the present invention, such example, But hexahydro furyl simultaneously [3,2-b] furans -2- base ethyls are not limited to, hexahydro furyl simultaneously [3,2-b] furans -2- ylmethyls, 7- azabicyclos [2.3.0] heptane -2- ylmethyls, 7- azabicyclos [2.3.0] heptane -2- base ethyls, 7- azabicyclos [2.3.0] heptane -4- ylmethyls etc..
Term " condensed-bicyclic base oxygroup " includes the condensed-bicyclic base optionally replaced, as defined in the present invention, connection It is connected with molecule rest part onto oxygen atom, and by oxygen atom, such example is including but not limited to l, and 2, 3,4,4a, 5,8,8a- octahydro naphthalene oxygroup, condensed-bicyclic [3.3.0] octane -2- oxygroups, condensed-bicyclic [3.1.0] Hexane -2- oxygroups etc..
Term " condensing miscellaneous bicyclic group oxygroup " includes the condensed miscellaneous bicyclic group optionally replaced, as defined in the present invention, It is connected on oxygen atom, and is connected with molecule rest part by oxygen atom, such example is including but not limited to six Hydrogen-furans simultaneously [3,2-b] furans -2- base oxygroups, 7- azabicyclos [2.3.0] heptane -2- base oxygroups, 7- azabicyclos [2.3.0] heptane -4- base oxygroups etc..
Term " condensed-bicyclic base amino " indicates that amino group is replaced by one or two condensed-bicyclic base, wherein thick Closing bicyclic group has meaning as described in the present invention, such example including but not limited to l, 2,3,4,4a, 5, 8,8a- octahydro naphthyl-aminos, two（1,2,3,4,4a, 5,8,8a- octahydro naphthalene）Amino, condensed-bicyclic [3.3.0] octyl amino, condensed-bicyclic [3.1.0] hexyl amino etc..
Term " condensing miscellaneous bicyclic group amino " indicates that amino group condenses miscellaneous bicyclic group by one or two and replaces, In condense miscellaneous bicyclic group have meaning as described in the present invention, such example including but not limited to hexahydro-furans simultaneously [3,2-b] furans -2- base amino, -2 base amino of 7- azabicyclos [2.3.0] heptane, 7- azabicyclos [2.3.0] heptane - 4- base amino etc..
Term " condensed-bicyclic base alkylamino " indicates that alkylamino radicals are replaced by one or more condensed-bicyclic bases, Middle condensed-bicyclic base has meaning as described in the present invention, such example including but not limited to l, 2,3,4,4a, 5,8,8a- octahydro napthylmethylaminos, two（1,2,3,4,4a, 5,8,8a- octahydro naphthalene）Methylamino condenses double Ring [3.3.0] octyl methylamino, condensed-bicyclic [3.1.0] hexyl methylamino etc..
Term " condensing miscellaneous bicyclic group alkylamino " indicates that alkylamino radicals condense miscellaneous bicyclic group by one or more and replace, Wherein condense miscellaneous bicyclic group have meaning as described in the present invention, such example including but not limited to hexahydro-furans simultaneously [3,2-b] furans -2- base methylaminos, 7- azabicyclos [2.3.0] heptane -2- base methylaminos, 7- azabicyclos [2.3.0] Heptane -4- base methylaminos etc..
Term " condensed-bicyclic base alkoxy " indicates that alkoxy is replaced by one or more condensed-bicyclic base groups, Middle alkoxy and condensed-bicyclic base have a meaning as described in the present invention, and such example is including but not limited to l, and 2, 3,4,4a, 5,8,8a- octahydro naphthylmethoxy, l, 2,3,4,4a, 5,8,8a- octahydro naphthalene ethyoxyls, Condensed-bicyclic [3.3.0] octane ethyoxyl, condensed-bicyclic [3.1.0] hexane-propoxyl group etc..
Term " condensing miscellaneous bicyclic group alkoxy " indicates that alkoxy condenses miscellaneous bicyclic group group by one or more and replaces, Wherein alkoxy and condensed miscellaneous bicyclic group has meaning as described in the present invention, and such example is including but not limited to six Simultaneously [3,2-b] furans -2- base propoxyl group, 7- azabicyclos [2.2.1] heptane -2- base oxethyls, 7- azepines are double for hydrogen-furans Ring [2.3.0] heptane -4- base propoxyl group, hexahydro-furans simultaneously [3,2-b] furans -2- base oxethyls, 7- azabicyclos [2.3.0] heptane -2- base propoxyl group, 7- azabicyclos [2.3.0] heptane -4- base oxethyls etc..
Term " condensed-bicyclic base oxygroup alkoxy " indicates alkoxy by one or more condensed-bicyclic base oxygroup groups institute Replace, wherein alkoxy and condensed-bicyclic base oxygroup include with meaning as described in the present invention, such example, but simultaneously It is not limited to l, 2,3,4,4a, 5,8,8a- octahydro naphthalene Oxymethoxies, l, 2,3,4,4a, 5,8,8a- Octahydro naphthalene oxygroup ethyoxyl, condensed-bicyclic [3.3.0] octane -2- oxygroup ethyoxyls, condensed-bicyclic [3.1.0] hexane -2- Oxygroup propoxyl group etc..
Term " condensing miscellaneous bicyclic group oxygroup alkoxy " indicates that alkoxy condenses miscellaneous bicyclic group oxygroup base by one or more Group is replaced, and wherein alkoxy and condensed miscellaneous bicyclic group oxygroup include with meaning as described in the present invention, such example, But it is not limited to hexahydro-furans simultaneously [3,2-b] furans -2- base oxygroup propoxyl group, 7- azabicyclos [2.2.1] heptane -2- bases Oxygroup ethyoxyl, 7- azabicyclos [2.3.0] heptane -4- base oxygroup propoxyl group, hexahydro-furans simultaneously [3,2-b] furans -2- Base oxygroup ethyoxyl, 7- azabicyclos [2.3.0] heptane -2- base oxygroup propoxyl group, 7- azabicyclos [2.3.0] heptane -4- Base oxygroup ethyoxyl etc..
Term " condensed-bicyclic base aminoalkoxy " indicates that alkoxy is replaced by one or more condensed-bicyclic base amino, Wherein alkoxy and condensed-bicyclic base amino have meaning as described in the present invention, such example including but not limited to L, 2,3,4,4a, 5,8,8a- octahydro naphthyl-amino ethyoxyl, l, 2,3,4,4a, 5,8,8a- octahydro naphthalenes Base amino propoxyl group, two（1,2,3,4,4a, 5,8,8a- octahydro naphthalene）Amino propoxyl group, condensed-bicyclic [3.3.0] octane -2- amino ethoxies, condensed-bicyclic [3.1.0] hexane -2- amino propoxyl group etc..
Term " condensing miscellaneous bicyclic group aminoalkoxy " indicates that alkoxy condenses miscellaneous bicyclic group amino institute by one or more Replace, wherein alkoxy and condensed miscellaneous bicyclic group amino include with meaning as described in the present invention, such example, but It is not limited to 7- azabicyclos [2.2.1] heptane -2- base amino ethoxies, 7- azabicyclos [2.3.0] heptane -4- base amino Propoxyl group, hexahydro-furans simultaneously [3,2-b] furans -2- base amino ethoxies, hexahydro-furans simultaneously [3,2-b] furans -2- bases Amino propoxyl group, hexahydro-furans simultaneously [3,2-b] furans -2- base aminomethoxies etc..
Term " loop coil base ", " loop coil ", " spiral shell bicyclic group ", " spiral shell is bicyclic " indicate a ring originating from another ring Particularly ring-shaped carbon.Such as disclosed below, the bridged-ring system of a saturation（Ring B and B '）It is referred to as " condensed double Ring ", otherwise a shared carbon atom in the member ring systems that be saturateds at two of ring A and ring B, then be referred to as " loop coil ".Inside loop coil Each ring be either carbocyclic ring or be heteroalicyclic.Such example is including but not limited to 2,7- diaza spiros [4.4] nonane -2- bases, 7- oxygen -2- azaspiros [4.5] decane -2- bases, 4- azaspiros [2.4] heptane -5- bases, 4- oxaspiros [2.4] heptane -5- bases, 5- azaspiros [2.4] heptane -5- bases, spiral shell [2.4] heptane base, spiral shell [4.4] nonyl, 7- hydroxyls - 5- azaspiros [2.4] heptane -5- bases etc..And the spiral shell bicyclic group can be substituted or non-substituted, and wherein substituent group can be with It is, but is not limited to, halogenated alkyl, oxo (=O), hydroxyl, amino, halogen, cyano, aryl, heteroaryl, alkane Oxygroup, alkylamino, alkyl, alkenyl, alkynyl, heterocycle, sulfydryl, nitro, aryloxy group, the alkoxy of hydroxyl substitution, Alkyl-the C (=O)-, alkyl-C (=O)-, alkyl-S (=O)-, alkyl-S (=O) of hydroxyl substitution2, the alkane of hydroxyl substitution Base-S (=O)-, the alkyl-S (=O) of hydroxyl substitution2, Carboxyalkoxy etc..
Term " the miscellaneous bicyclic group of spiral shell " indicates a ring originating from particularly ring-shaped carbon on another ring.Such as institute above Description, the bridged-ring system of a saturation（Ring B and B '）It is referred to as " condensed-bicyclic ", on the contrary what ring A and ring B was saturated at two A carbon atom is shared in member ring systems, then is referred to as " loop coil ".And at least one member ring systems include one or more hetero atoms, Wherein each member ring systems include 3-7 membered rings, that is, include 1-6 carbon atom and be N, O, P, the 1-3 hetero atom of S, This S or P optionally is replaced to obtain as SO, SO by one or more oxygen atoms2, PO, PO2, group, such example Including but not limited to 4- azaspiros [2.4] heptane -5- bases, 4- oxaspiros [2.4] heptane -5- bases, 5- azaspiros [2.4] Heptane -5- bases, 7- hydroxyl -5- azaspiros [2.4] heptane -5- bases etc..And the miscellaneous bicyclic group of spiral shell can be substitution or non-take Generation, wherein substituent group can be, but be not limited to, halogenated alkyl, oxo (=O), hydroxyl, amino, halogen, cyanogen Base, aryl, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, heterocycle, sulfydryl, nitro, fragrant oxygen Base, the alkoxy of hydroxyl substitution, the alkyl-C (=O)-, alkyl-C (=O)-, alkyl-S (=O)-, alkyl-S of hydroxyl substitution (=O)2, the alkyl-S (=O)-of hydroxyl substitution, the alkyl-S (=O) of hydroxyl substitution2, Carboxyalkoxy etc..
Term " spiral shell bicyclic group aliphatic " indicates that aliphatic group is replaced by one or more spiral shell bicyclic group groups, Middle aliphatic group and spiral shell bicyclic group group have a meaning as described in the present invention, such example including but not limited to Spiral shell [2.4] heptane ylmethyl, spiral shell [2.4] heptane base ethyl, spiral shell [2.4] heptane base propyl, spiral shell [4.4] nonane ylmethyl, Spiral shell 4.4] nonyl ethyl, 4- azaspiros [2.4] heptane -5- ylmethyls, 4- azaspiros [2.4] heptane -5- base ethyls, 4- Oxaspiro [2.4] heptane -5- base ethyls, 5- azaspiros [2.4] heptane -5- base propyl, 7- hydroxyl -5- azaspiros [2.4] heptan Alkane -5- base propyl etc..
Term " the miscellaneous bicyclic group aliphatic of spiral shell " indicates that aliphatic group is replaced by the miscellaneous bicyclic group group of one or more spiral shells, Wherein the miscellaneous bicyclic group group of aliphatic group and spiral shell has meaning as described in the present invention, and such example includes, but not It is limited to 4- azaspiros [2.4] heptane -5- ylmethyls, 4- azaspiros [2.4] heptane -5- base ethyls, 4- oxaspiros [2.4] heptan Alkane -5- base ethyls, 5- azaspiros [2.4] heptane -5- base propyl, 7- hydroxyl -5- azaspiros [2.4] heptane -5- base propyl etc..
Term " spiral shell bicyclic group oxygroup " includes that the spiral shell bicyclic group optionally replaced is connected to oxygen as defined in the present invention On atom, and it is connected with molecule rest part by oxygen atom, such example is including but not limited to spiral shell [2.4] heptan Alkane -2- oxygroups, spiral shell [2.4] heptane -3- oxygroups, spiral shell [2.4] heptane -4- oxygroups, spiral shell [4.4] nonane -2- oxygroups, spiral shell [4.4] nonane -4- oxygroups, 4- azaspiros [2.4] heptane -5- oxygroups etc..
Term " the miscellaneous bicyclic group oxygroup of spiral shell " includes the miscellaneous bicyclic group of spiral shell optionally replaced, as defined in the present invention, connection It is connected with molecule rest part onto oxygen atom, and by oxygen atom, such example is including but not limited to 4- azepines Spiral shell [2.4] heptane -5- base oxygroups, 4- oxaspiros [2.4] heptane -5- base oxygroups, 5- azaspiros [2.4] heptane -5- base oxygroups Deng.
Term " spiral shell bicyclic group amino " indicates that amino group is replaced by one or two spiral shell bicyclic group group, wherein spiral shell Bicyclic group has meaning as described in the present invention, such example including but not limited to spiral shell [2.4] heptane -2- amino, Spiral shell [2.4] heptane -3- amino, spiral shell [2.4] heptane -4- amino, spiral shell [4.4] nonane -2- amino, spiral shell [4.4] nonane -4- ammonia Base, 4- azaspiros [2.4] heptane -5- amino etc..
Term " the miscellaneous bicyclic group amino of spiral shell " indicates that amino group is replaced by the miscellaneous bicyclic group group of one or two spiral shell, The middle miscellaneous bicyclic group of spiral shell has meaning as described in the present invention, and such example is including but not limited to 4- azaspiros [2.4] heptan Alkane -5- base amino, 4- azaspiros [2.4] heptane -2- base amino, 4- oxaspiros [2.4] heptane -5- base amino, 5- azaspiros [2.4] heptane -5- bases amino etc..
Term " spiral shell bicyclic group alkoxy " indicates that alkoxy base is replaced by one or more spiral shell bicyclic groups, wherein spiral shell Bicyclic group and alkoxy base have meaning as described in the present invention, and such example is including but not limited to spiral shell [2.4] heptan Alkane -2- methoxyl groups, spiral shell [2.4] heptane -3- ethyoxyls, spiral shell [2.4] heptane -4- ethyoxyls, spiral shell [4.4] nonane -2- methoxies Base, spiral shell [4.4] nonane -4- propoxyl group, 4- azaspiros [2.4] heptane -5- methoxyl groups etc..
Term " the miscellaneous bicyclic group alkoxy of spiral shell " indicates that alkoxy base is replaced by the miscellaneous bicyclic group of one or more spiral shells, The miscellaneous bicyclic group of middle spiral shell and alkoxy base have meaning as described in the present invention, and such example is including but not limited to 4- Azaspiro [2.4] heptane -5- ylmethoxies, 4- azaspiros [2.4] heptane -2- base oxethyls, 4- oxaspiros [2.4] heptane - 5- base oxethyls, 5- azaspiros [2.4] heptane -5- base propoxyl group etc..
Term " spiral shell bicyclic group alkylamino " indicates that alkylamino radicals are replaced by one or more spiral shell bicyclic groups, wherein spiral shell Bicyclic group and alkylamino radicals have meaning as described in the present invention, and such example is including but not limited to spiral shell [2.4] heptan Alkane -2- methylaminos, spiral shell [2.4] heptane -3- ethylaminos, spiral shell [2.4] heptane -4- ethylaminos, spiral shell [4.4] nonane -2- first ammonia Base, spiral shell [4.4] third amino of nonane -4-, 4- azaspiros [2.4] heptane -5- methylaminos etc..
Term " the miscellaneous bicyclic group alkylamino of spiral shell " alkylamino radicals are replaced by the miscellaneous bicyclic group of one or more spiral shells, wherein spiral shell Miscellaneous bicyclic group and alkylamino radicals have meaning as described in the present invention, and such example is including but not limited to 4- azepines Spiral shell [2.4] heptane -5- base methylaminos, 4- azaspiros [2.4] heptane -2- base ethylaminos, 4- oxaspiros [2.4] heptane -5- bases Ethylamino, 5- azaspiros [2.4] heptane -5- third amino of base etc..
Term " spiral shell bicyclic group oxygroup alkoxy " indicates that alkoxy is replaced by one or more spiral shell bicyclic group oxygroup groups, Wherein spiral shell bicyclic group oxygroup and alkoxy base have meaning as described in the present invention, and such example includes, but and unlimited In spiral shell [2.4] heptane -2- oxygroup ethyoxyls, spiral shell [2.4] heptane -3- oxygroup propoxyl group, spiral shell [2.4] heptane -4- the third oxygen of oxygroup Base, spiral shell [4.4] nonane -2- oxygroup ethyoxyls, spiral shell [4.4] nonane -4- oxygroup propoxyl group, 4- azaspiros [2.4] heptane -5- Oxygroup propoxyl group etc..
Term " the miscellaneous bicyclic group oxygroup alkoxy of spiral shell " indicates alkoxy by the miscellaneous bicyclic group oxygroup group institute of one or more spiral shells Replace, wherein the miscellaneous bicyclic group oxygroup of spiral shell and alkoxy base include with meaning as described in the present invention, such example, But 4- azaspiros [2.4] heptane -5- base oxygroup ethyoxyls are not limited to, 4- oxaspiros [2.4] heptane -5- base oxygroup ethyoxyls, 5- azaspiros [2.4] heptane -5- base oxygroup ethyoxyls, 4- azaspiros [2.4] heptane -5- base oxygroup propoxyl group, 4- oxaspiros [2.4] heptane -5- bases oxygroup propoxyl group, 5- azaspiros [2.4] heptane -5- base oxygroup propoxyl group etc..
Term " spiral shell bicyclic group aminoalkoxy " indicates that alkoxy is replaced by one or more spiral shell bicyclic group amino, Middle alkoxy and spiral shell bicyclic group amino have meaning as described in the present invention, and such example is including but not limited to spiral shell [2.4] heptane -2- amino ethoxies, spiral shell [2.4] heptane -3- amino propoxyl group, spiral shell [2.4] heptane -4- amino ethoxies, Spiral shell [4.4] nonane -2- amino ethoxies, spiral shell [4.4] nonane -4- amino propoxyl group, 4- azaspiros [2.4] heptane -5- amino Propoxyl group etc..
Term " the miscellaneous bicyclic group aminoalkoxy of spiral shell " indicates that alkoxy is replaced by the miscellaneous bicyclic group amino of one or more spiral shells, Wherein the miscellaneous bicyclic group amino of alkoxy and spiral shell have meaning as described in the present invention, such example including but not limited to 4- azaspiros [2.4] heptane -5- base amino ethoxies, two oxygroup of 4- azaspiros [2.4] heptane -2- bases amino, 4- oxaspiros [2.4] heptane -5- bases amino ethoxy, 5- azaspiros [2.4] heptane -5- base amino propoxyl group etc..
Unless other aspects show that structural formula described in the invention includes all isomeric forms（As mapping is different Structure, diastereo-isomerism, and geometrical isomerism（Or conformational isomerism））：Such as R, S configuration containing asymmetric center, double bond (Z), (E) isomers, and (Z), (E) rotamer.Therefore, the single three-dimensional chemical isomer of the compound of the present invention Or its enantiomter, diastereoisomer, or geometric isomer（Or rotamer）Mixture belong to the present invention Range.
Term " prodrug " used in the present invention represents a compound and is converted into chemical combination shown in Formulas I-X in vivo Object.Such conversion is hydrolyzed by pro-drug or is influenced for precursor structure through enzymatic conversion in blood or tissue in blood. Pro-drug compounds of the present invention can be ester, and ester can have phenyl ester class as pro-drug in existing invention, Aliphatic (C1-C24) esters, pivaloyloxymethyl esters, carbonic ester, carbamates and amino acid esters.Such as this hair A compound in bright includes hydroxyl, can be acylated to obtain the compound of prodrug form.Other precursor medicines Object form includes phosphate, if these phosphate compounds are being obtained through the di on parent.About precursor medicine Object, which completely discusses, can refer to following documents：T. Higuchi and V.Stella, Pro-drugsas Novel Delivery Systems, Vol. 14 of the A.C.S.Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, J. Rautio et al, Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and S.J. Hecker et al, Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51, 2328-2345.
Unless other aspects show, all tautomeric forms of the compound of the present invention be included in the scope of the present invention it It is interior.In addition, unless other aspects show, the structural formula of compound described in the invention includes one or more different originals The enriched isotope of son.
" metabolite " refers to specific compound or its salt product obtained by metabolic action in the body.One change Closing the metabolite of object can be identified that activity can pass through institute such as of the present invention by technology well-known in the art It adopts as description and is experimentally characterized.Such product can be by, by aoxidizing, being gone back to drug compound Original, hydrolysis, amidated, deamidation, esterification, degreasing, the methods of enzymatic lysis etc. obtain.Correspondingly, this hair The bright metabolite for including compound, including the compound of the present invention and mammal were come into full contact with produced by a period of time Metabolite.
The compound of the present invention can include asymmetric center or chiral centre, therefore there are different stereoisomers. All stereoisomeric forms in any ratio of the compound of the present invention, including but not limited to, diastereomer, enantiomter, resistance turn Isomers, and their mixture, such as racemic mixture constitute the part of the present invention.Many organic compounds are all Exist with optical active forms, i.e. the plane of their capable Plane of rotation polarised lights.When describing optically active compound, Prefix D, L or R, S are used for indicating the absolute configuration at molecular chiral center.Prefix D, L or（+）、（-）For naming chemical combination object plane The symbol of polarised light rotation,（-）Or it is left-handed, prefix that L, which refers to compound,（+）Or it is dextrorotation that D, which refers to compound,.These The chemical constitution of stereoisomer is identical, but their stereochemical structure is different.Specifically stereoisomer can be The mixture of enantiomer, isomers is commonly referred to as enantiomeric mixture.50：50 mixture of enantiomers is referred to as outer disappear Mixture or racemic modification are revolved, this may lead to do not have stereoselectivity or stereoselectivity in chemical reaction process.Term " racemic mixture " and " racemic modification " refers to the mixture of equimolar two enantiomters, lacks optical activity.
Term " tautomer " or " tautomeric form " refer to that the isomer of the structure of different-energy can be with Pass through the mutual inversion of phases of low energy barrier.Such as proton tautomer（I.e. prototropic tautomer）Including passing through proton transfer Change, such as the isomerization of keto-enol and imine-enamine.Valence（Chemical valence）Tautomer includes Recombinate the change of bonding electrons.
" pharmaceutically acceptable salt " used in the present invention refers to the organic salt and inorganic salts of the compound of the present invention.Medicine Acceptable salt is known to us in fields on, such as document：S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19,1977. recorded.The salt that pharmaceutically acceptable nontoxic acid is formed is including but not limited to ammonia Base group, which reacts the inorganic acid salt to be formed, a hydrochloride, hydrobromate, phosphate, sulfate, perchlorate, and organic Hydrochlorate, such as acetate, oxalates, maleate, tartrate, citrate, succinate, malonate, or These salt are obtained by other methods described in the books or literature such as ion-exchange.Other pharmaceutically acceptable salt packets It includes:Adipate, alginates, ascorbate, aspartate, benzene sulfonate, benzoate, bisulphate, Borate, butyrate, camphor hydrochlorate, camsilate, cyclopentyl propionate, digluconate, dodecyl sulphur Hydrochlorate, esilate, formates, fumarate, gluceptate, glycerophosphate, gluconate, half Sulfate, enanthate, caproate, hydriodate, 2- hydroxy-ethanesulfonate salts, lactobionate, lactate, lauric acid Salt, lauryl sulfate, malate, malonate, mesylate, 2- naphthalene sulfonates, nicotinate, nitrate, Oleate, palmitate, pamoate, pectate, persulfate, 3- phenylpropionic acid salt, picrate, pivalic acid Salt, propionate, stearate, rhodanate, tosilate, undecylate, valerate, etc..By appropriate The obtained salt of alkali include alkali metal, alkaline-earth metal, ammonium and N+(C1-C4 alkyl)4Salt.The present invention is also intended to contemplate any The compound of the group of included N is formed by quaternary ammonium salt.Water-soluble or oil-soluble or dispersion product can be turned by quaternary ammonium With obtaining.Alkali or alkaline earth metal salt includes sodium, lithium, potassium, calcium, magnesium, etc..Pharmaceutically acceptable salt is further Including appropriate, nontoxic ammonium, the amine cation that quaternary ammonium salt and gegenions are formed, such as halide, hydroxide, carboxylic Compound, hydrosulphate, phosphoric acid compound, nitric acid compound, C1-C8 azochlorosulfonate acid compounds and aromatic sulphonic acid compound.
The salt of the part of compounds of the present invention can be illustrated with the salt for the particular compound listed as follows, but not limited The present invention：
。
" solvate " of the present invention refers to that one or more solvent molecules are formed by association with the compound of the present invention Object.The solvent of solvate is formed including but not limited to, water, isopropanol, ethyl alcohol, methanol, dimethyl sulfoxide, acetic acid Ethyl ester, acetic acid, ethylaminoethanol.Term " hydrate " refers to that solvent molecule is that water is formed by associated matter.
The solvate of part of compounds or the solvate of its salt of the present invention can use the specific chemical combination listed as follows The salt of object illustrates, but does not limit the present invention：
。
The present invention includes the application of the compounds of this invention and its pharmaceutically acceptable salt, is controlled for producing medical product Treat patient's disease caused by inflammation, immune system disorder etc., including those diseases described in the invention.The present invention includes Pharmaceutical composition, the pharmaceutical composition include the compound and at least one pharmaceutically acceptable carrier representated by Formulas I-X, Excipient, diluent, adjuvant, effective therapeutic dose needed for the combination of medium.
The present invention equally includes treatment or mitigates patient's disease caused by inflammation, immune system disorder etc., or to this disease The method of disease sensitivity, this method include to be treated to patient using the therapeutically effective amount of compound representated by Formulas I-X.
Unless other aspects show, all stereoisomers of the compound of the present invention, geometric isomer mutually makes a variation Structure body, nitrogen oxides hydrates, solvate, metabolite, salt and pharmaceutically acceptable prodrug belong to the present invention Range.
Specifically, salt is pharmaceutically acceptable salt.Term " pharmaceutically acceptable " includes substance or composition must Must be suitble to chemistry or toxicologically, it is related with the other components of composition preparation and mammal for treatment.
The salt of the compound of the present invention further includes being used to prepare or purifying the intermediate of compound or Formulas I-X shown in Formulas I-X The salt of the enantiomter of shown compound separation, but it is not necessarily pharmaceutically acceptable salt.
If the compound of the present invention is alkaline, then conceivable salt can be by provided in the literature any suitable Method be prepared, for example with inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid etc..Or make With organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, hydroxyl second Acid and salicylic acid;Pyrans saccharic acid, such as glucuronic acid and galacturonic acid;Alpha-hydroxy acid, such as citric acid and tartaric acid;Ammonia Base acid, such as asparatate and glutamic acid;Aromatic acid, such as benzoic acid and cinnamic acid;Sulfonic acid, such as p-methyl benzenesulfonic acid, Ethanesulfonic acid, etc..
If the compound of the present invention is acid, then conceivable salt can be prepared by suitable method, Such as, using inorganic base or organic base, such as ammonia（Primaquine, parahelium, tertiary ammonia）, alkali metal hydroxide or alkaline-earth metal hydrogen-oxygen Compound, etc..Suitable salt is including but not limited to, organic salt obtained from amino acids, such as glycine and arginine, Ammonia, such as primaquine, parahelium and tertiary ammonia, and ring-type ammonia, such as piperidines, morpholine and piperazine etc. and from sodium, calcium, potassium, magnesium, manganese, Iron, copper, zinc, aluminium and lithium obtain inorganic salts.
According to another fragrant face, the characteristics of pharmaceutical composition of the invention includes the compound of Formulas I-X, listed by the present invention Compound, or embodiment compound represented, and pharmaceutically acceptable carrier, adjuvant, or excipient.The present invention's It is fine caused by inflammation, immune system disorder etc. effectively detectably to treat or mitigate patient for the amount of compound in composition Dimensionization disease.
There are free forms for the compound of the present invention, or it is suitable, as pharmaceutically acceptable derivates.According to this Invention, pharmaceutically acceptable derivates are including but not limited to, pharmaceutically acceptable prodrug, salt, ester, esters Salt, or other any adducts or derivative that can be directly or indirectly administered according to the needs of patient, the present invention other Compound described in aspect, metabolite or his residue.
As described in the invention, the pharmaceutically acceptable composition of the present invention further includes pharmaceutically acceptable Carrier, adjuvant, or excipient, these are applied as the present invention, including any solvent, diluent, or other liquid Excipient, dispersant or suspending agent, surfactant, isotonic agent, thickener, emulsifier, preservative, solid adhesion Agent or lubricant, etc., it is suitable for distinctive target formulation.As described in following documents：In Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D. B. Troy, Lippincott Williams&Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York. the content of comprehensive document herein, show different carriers can be applied to pharmaceutically acceptable composition preparation and Their well known preparation methods.In addition to any conventional carrier medium range incompatible with the compound of the present invention, such as institute Any undesirable biological effect of generation is produced in harmful manner with any other component of pharmaceutically acceptable composition Raw interaction, their purposes are also the range that the present invention is considered.
The substance of pharmaceutically acceptable carrier be can be used as including but not limited to, ion-exchanger, aluminium, stearic acid Aluminium, lecithin, haemocyanin, such as human albumin, buffer substance such as phosphate, glycine, sorbic acid, sorbic acid Potassium, the partial glyceride mixtures of saturated vegetable fatty acid, water, salt or electrolyte, such as protamine sulfate, phosphoric acid hydrogen Disodium, potassium hydrogen phosphate, sodium chloride, zinc salt, colloidal silicon, magnesium trisilicate, polyvinylpyrrolidone, polyacrylate, Wax, polyethylene-polyoxypropylene-blocking condensate, lanolin, sugar, such as lactose, dextrose and saccharose;Starch such as corn Starch and potato starch;Cellulose and its derivative such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; Gum powder;Malt;Gelatin;Talcum powder;Auxiliary material such as cocoa butter and suppository wax;Oil such as peanut oil, cotton seed oil, Safflower oil, sesame oil, olive oil, corn oil and soya-bean oil;Glycol compound, such as propylene glycol and polyethylene glycol;Esters are such as Ethyl oleate and ethyl laurate;Agar;Buffer such as magnesium hydroxide and aluminium hydroxide;Alginic acid;It is pyrogen-free Water;Isotonic salt;Lin Ge（Family name）Solution;Ethyl alcohol, phosphate buffer solution, and other nontoxic suitable lubricant such as bays Sodium sulphate and magnesium stearate, colorant, releasing agent, coating agents, sweetener, flavoring agent and fragrance, preservative and anti- Oxidant.
The pharmaceutical composition of the present invention can be oral medication, drug administration by injection, Aerosol inhalation, local administration, warp Rectally, nose administration, buccal administration or are administered vagina administration by implantable medicine box.Can be capsule, tablet, Pill, pulvis, granula and water suspension or solution.Oral medication can use following form：Tablet, capsule, can divide pill Scattered powder, particle or suspension, syrup and elixir, or be administered in a manner of external application：Ointment, gel, drug containing adhesive plaster etc., Or parenteral routes are carried out with sterile injectable solution or suspension form.The compounds of this invention also can parenteral or intraperitoneal Administration.Also surfactant can properly mixed（Such as hydroxypropyl cellulose, polyvinylpyrrolidone）Water in prepare these Reactive compound（As free alkali or pharmaceutically acceptable salt）Solution or suspension.It can also be in glycerine, liquid, poly- second two Dispersion liquid is prepared in alcohol and its mixture in the oil.Under conventional storage and use condition, contain preservative in these preparations To prevent microorganism from growing.
Medicament forms suitable for injection include：Aseptic aqueous solution or dispersion liquid and aseptic powder（It is noted for extemporaneous preparation of sterile Penetrate solution or dispersion liquid）.In all cases, these forms must be sterile and must be that fluid is arranged with being easy to syringe Go out fluid.It must be stable under conditions of manufacture and storage, and must be able to prevent microorganism（Such as bacterium and fungi）Pollution It influences.Carrier can be solvent or decentralized medium, wherein containing such as water, alcohol（Such as glycerine, propylene glycol and liquid polyethylene glycol）、 They properly mix object and vegetable oil.
Compound can be applied with local mode, without being applied with system mode.Such as usually to dilute preparation or continue The form of delivery formulations will be in compound direct injection to organ.In addition, the pharmaceutical composition containing the compounds of this invention can be with It uses in targeted drug delivery system, such as is delivered in the liposome being coated with organ specific antibody.The liposome The organ will be targeted and absorbed by the Organic selection.In addition, the composition containing the compounds of this invention can be with fast quick-release The form for putting preparation, timed release preparations or IR formulation provides.
Sucking is applied, the compound of the present invention can be aerosol, aerosol or powder type.Chemical combination of the present invention The pharmaceutical composition of object can be delivered easily in the form of aerosol spray, and the aerosol spray can be mounted in pressure In container or atomizer, suitable propellant such as dicholorodifluoromethane, Arcton 11, dichlorotetra-fluoroethane, dioxy are used Change carbon or other suitable gases.In the case of pressurized aerosol, dosage unit can be determined by valve to deliver Metered amount.Such as by taking capsule and cylindrantherae as an example, it can be prepared as containing describedization for the gelatin of inhalator or insufflator Close the mixture of powders of object and appropriate powdered substrate such as lactose or starch.
The compounds of this invention can also be prepared as rectal compositions such as enema, Gel in rectal administered, rectal foams agent, straight Intestines aerosol, suppository, gel suppository（gel suppository）Or enema,retention（retention enema）, wherein containing There is conventional suppository base such as cocoa butter or other glyceride and synthetic polymer such as polyvinylpyrrolidone, PEG. In the suppository form of composition, it is optionally first with the mixture of cocoa butter that low melt wax is such as, but not limited to fatty glyceride First it is melted.
In addition, the compounds of this invention can also have immunoloregulation function and anti-inflammatory, anti-fibrosis with other at least one Drug, be specifically including but not limited to, imuran, cyclophosphamide, prednisone, prednisolone, aspirin, to acetyl ammonia Base phenol, Indomethacin, naproxen, Nabumetone, Diclofenac, brufen, aulin, rofecoxib, celecoxib, left-handed miaow Azoles, interleukins, interferon, transfer factor, thymosin extrasin, antilymphocyte globulin (ALG), cyclosporine, Mycophenolate Mofetil etc..
Pharmaceutical composition can be prepared according to the usual manner acceptable carrier of one or more physiology, wherein wrapping Include the excipient and adjuvant that can help that reactive compound is processed as to pharmaceutical preparations.Selected administration method determines appropriate Dosage form.Technology, carrier and excipient known to any can understand use appropriate according in the prior art.Contain this hair The pharmaceutical composition of bright compound can be prepared according to conventional methods, for example, by conventional mixing, dissolving, pelletize, ingot processed, It is prepared by grinding, emulsification, packing, encapsulating or pressing process.
Pharmaceutical composition will include at least one pharmaceutical acceptable carrier, diluent or excipient and free acid, free alkali or can The compound of the present invention of acceptable salt is as active constituent.In addition, pharmaceutical composition may also include other medicine or pharmacy Activating agent, carrier, adjuvant, such as preservative, stabilizer, wetting agent or emulsifier, dissolution accelerator, adjust osmotic pressure salt or Buffer.In addition, pharmaceutical composition also contains other substances for having therapeutic value.
The preparation method of composition containing compound described herein include by compound with it is one or more it is inert can Pharmaceutical excipient or carrier are prepared as solid, semisolid or liquid form together.Solid composite includes but not limited to powder, piece Agent, dispersible granule, capsule, cachet and suppository.Liquid composition includes wherein being dissolved with the solution of compound, containing Emulsion, the solution containing the liposome comprising compound disclosed herein, micelle or nano-particle for having compound.Semisolid group It includes but not limited to gelling agent, suspension and cream to close object.Composition can be aqueous agent or suspended form, be suitble to In the solid form or emulsion form that are dissolved or suspended in before use in liquid.These compositions can also contain a small amount of nontoxic Adjuvant, such as wetting agent or emulsifier, pH buffer etc..
The compound of the present invention is preferably prepared into dosage unit form to mitigate the equal of dosage and dosage by pharmaceutical formulation Even property.Term " dosage " unit type " obtains suitably treating the physical dispersion unit of required drug referred to herein as patient.However It should be appreciated that the compound of the present invention or the daily total usage of composition will be judged by attending physician according to reliable medicine range To determine.Specific effective dose level will include quilt depending on many factors for any one special patient or organism The illness for the treatment of and the seriousness of illness, the activity of particular compound, concrete composition used, the age of patient, body Weight, health status, gender and eating habit, administration time, the discharge rate of administration route and particular compound used are controlled The duration for the treatment of, medicinal application is combined in drug combination or with specific compound, and some other pharmaceutical field Well known factor.
The compounds of this invention can be modified by the functional group of additional suitable to improve selectivity organism characteristic.This The modification of sample is that this field is known and include to biological lacuna（Such as blood, lymphatic system, central nervous system）Infiltration, It improves Oral Availability, improve dissolubility so as to which the modification of excretion is metabolized and changed by drug administration by injection, change.It can incite somebody to action The compounds of this invention is modified by the functional group of additional suitable to improve selectivity organism characteristic.Such modification is ability Domain is known and includes to biological lacuna（Such as blood, lymphatic system, central nervous system）Infiltration, raising are oral effective Property, improve dissolubility so as to pass through drug administration by injection, change metabolism and change excretion modification.
Embodiment 1
The fluoro- 5- methyl of 2- -5HPyrrolo- [1,2-c] quinoline -6,11- diketone
Step 1）The chloro- 6- fluorine quinoline -4- methyl formates of the bromo- 2- of 3-
It weighs the chloro- 6- fluorine quinoline -4- methyl formates of 2- (4.7 mmol) and is dissolved in chloroform (20 mL), room temperature is added thereto It is stirred at room temperature 4 hours after 85% metachloroperbenzoic acid (6.8 mmol).Tribromo oxygen phosphorus (6.9 mmol) is added toward reaction solution Chloroformic solution (20 mL) stirs 1 hour afterwards.Reaction solution is poured into ice water after reaction, with unsaturated carbonate potassium solution tune pH For value to 8, dichloromethane extracts (100 mL × 2).Merge organic phase, organic phase saturated common salt water washing, anhydrous sodium sulfate It is dry, filtering, organic phase concentration.Residue is through column chromatography (EtOAc: PET = 1 :60) the chloro- 6- fluorine quinolines of the bromo- 2- of 3- are obtained Quinoline -4- methyl formates (64% yield).
Step 2）3-(1-（Tert-butoxycarbonyl）Pyrroles -2- bases) the chloro- 6- fluorine quinoline -4- methyl formates of -2-
Weigh the chloro- 6- fluorine quinoline -4- methyl formates of the bromo- 2- of 3- (3.2 mmol) and (1- (1- (tertbutyloxycarbonyl) pyrroles -2- bases) Boric acid (3.3 mmol) is dissolved in 1,4- dioxane (15 mL) and water (6 mL), and cesium carbonate (6.5 is added thereto ) and tetrakis triphenylphosphine palladium (0.3 mmol) mmol.Reaction solution is 75oIt is stirred 3 hours under C.Reaction solution is fallen after reaction Enter in ice water, is extracted with ethyl acetate (100 mL × 2).Merge organic phase, organic phase saturated common salt water washing is anhydrous Sodium sulphate is dried, filtering, organic phase concentration.Residue is through column chromatography (EtOAc: PET = 1:30) 3- (1- are obtained（Tertiary fourth oxygen Base carbonyl）Pyrroles -2- bases) the chloro- 6- fluorine quinoline -4- methyl formates of -2- (43% yield).
Step 3）The fluoro- 2- oxos -3- of 6- (- 2 base of pyrroles) -1,2- dihydroquinoline -4- methyl formates
By 3- (1-（Tert-butoxycarbonyl）Pyrroles -2- bases) the chloro- 6- fluorine quinoline -4- methyl formates of -2- (1.7 mmol) are dissolved in second Sour (10 mL), ethyl alcohol (6 mL), water（5 ml）After be warming up to 80oC reacts 18 hours.Vacuum distillation removes acetic acid, second Alcohol, gained residue are diluted with water, and are adjusted to meta-alkalescence with ammonium hydroxide, ethyl acetate extracts (100 mL × 2).Merge organic phase, Organic phase saturated common salt water washing, anhydrous sodium sulfate drying, filtering, organic phase concentration.Residue is through column chromatography (EtOAc: PET = 2:1) obtaining the fluoro- 2- oxos -3- of 6- (- 2 base of pyrroles) -1,2- dihydroquinoline -4- methyl formates, (44% receives Rate).
Step 4）The fluoro- 5- methyl of 2- -5HPyrrolo- [1,2-c] quinoline -6,11- diketone
By the fluoro- 2- oxos -3- of 6- (- 2 base of pyrroles) -1,2- dihydroquinoline -4- methyl formates (0.18 mmol), potassium carbonate (0.054 mmol), is dissolved in 20 mL of acetonitrile and dimethyl sulfoxide 2 mL, and 60oC stirs 12 h, adds bromomethane（0.20 mmol）.Reaction solution is poured into ice water after reaction, with dilute hydrochloric acid solution tune pH value to neutrality, ethyl acetate extraction（50 mL×2）, merging organic phase, organic phase saturated common salt water washing, anhydrous sodium sulfate drying is filtered, organic phase concentration, Residue is through silica gel column chromatography (EtOAc: PET = 1:3) the fluoro- 5- methyl of 2- -5HPyrrolo- [1,2-c] quinoline -6,11- Diketone（36% yield）.
ESI-MS m/z : 269.06 [M+H]+。
Embodiment 2
Anti-fibrosis active testing
The method of cell experiment
1. cell inoculation
The BHK-21 cells for taking exponential phase of growth, when cell growth fusion 85 95%, the digestion of routine passage method is collected thin Born of the same parents, cell count, adjustment cell density to 2 × 104A/mL is inoculated in 96 porocyte culture plates, 100μThe holes L/, At 37 °C, 5% CO2Under the conditions of be incubated.
2 cell administrations
After adherent 24 h of cell inoculation, supernatant is abandoned, changes the culture solution 100 of each compound concentration gradient containing above-mentioned preparationμThe holes L/, 3 multiple holes of each concentration group continue to cultivate 48 h after dosing.
The measurement of 3 absorbance values
After 48 h of dosing, 10 are added per holeμL (l/10 of nutrient solution volume) CCK-8 solution, after being incubated 2 h in incubator, The absorbance in each hole is detected at 450 nm of microplate reader（A）Value.The cell inhibitory effect of each compound is calculated according to surveyed A values Rate, cell proliferation inhibition rate（inhibition ratio, IR) = （L- experimental groups（Ai）Value/control group（A0）Value）× 100%, data processing software calculate separately each compound 48 h IC50Value.
Compound number IC50（mM）
1 B
2 C
3 B
5 C
8 B
16 C
17 B
19 C
20 B
25 C
27 B
29 B
37 C
40 B
41 B
44 C
45 B
50 C
52 B
54 B
55 C
59 B
60 C
63 B
66 B
70 C
75 B
76 C
77 B
PFD（Pirfenidone） C
Note：" A " indicates that compound concentration is to indicate that compound concentration is 0.05-5.0 mM less than 0.05 mM, " B " in table, " C " indicates that compound concentration is 5-20 mM, and " D " indicates that compound concentration is 20-100 mM;
The common trait of organ fibrosis is extracellular matrix（ECM）Over-deposit, the reconstruction of organ-tissue structure, many of which Cell factor takes part in this process.It is screened by In vitro cell experiment, the compound activity in the present invention is better than positive drug pyrrole Non- Buddhist nun's ketone;And the phototoxic reaction that pirfenidone has, safety higher, in anti-fibre is not present in the compound in the present invention There is better potential application foreground in terms of dimensionization.
Embodiment 3
Immunocompetence test the leading reference Vogl, S. of the compounds of this invention 1-89; Atanasov, A. G.; Binder, M.; Bulusu, M.; Zehl, M.;Fakhrudin, N.; Heiss, E. H.; Picker, P.; Wawrosch, C.; Saukel, J.;Reznicek, G.; Urban, E.; Bochkov, V.; Dirsch, V. M.; Kopp, B. J. Evid.-Based Complementary Altern. Med. 2013, ID 395316.
It tests the compound of the present invention 1-89 and inhibits the active abilities of NF- κ B, initial concentration 30μM。
The compound of the present invention 1-89 is further analyzed to determine its corresponding IC50Value
The compound of the present invention 1-89 inhibits the active IC50 values of NF- κ B
Number IC50（μM）
Parithenolide +++
1 +++
2 ++
3 +++
5 ++
8 ++
16 ++
17 ++
19 +++
20 ++
25 ++
27 +++
29 +++
37 ++
40 ++
41 +++
44 ++
45 +++
50 ++
52 ++
54 ++
55 ++
59 +++
60 ++
63 ++
66 +++
70 +++
75 ++
76 ++
77 +++
81 +++
85 +++
Note：" +++ ++ " indicate IC50Worth range is 0.001-0.1μM;" ++++" indicate IC50Worth range is 0.1-1.0μ M;" +++ " indicates IC50Worth range is 1.0-10μM;" ++ " indicates IC50Worth range is 10-50μM;"+" indicates IC50Value It is 50-100 to obtain rangeμM.
Majority of compounds activity is suitable with positive controls higher than positive controls or activity in the present invention;In the present invention Compound has the preferable activity for inhibiting NF- κ B, therefore has good application prospect in terms of immunological regulation.

Claims (12)

1. the alkaloid compound containing double lactams of a kind of Formulas I, Formula II structure, tautomer, stereoisomer, Racemic modification, the non-equal amount of mixture of enantiomter, geometric isomer, solvate, pharmaceutically acceptable salt or its salt Solvate, it is characterised in that Formulas I, Formula II compound have the following structure：
,
R1, R2, R3And shown in A, B be defined as follows：
A, B are five yuan or hexa-atomic of aromatic ring or hetero-aromatic ring, saturated or unsaturated carbocyclic ring or carbon heterocyclic; “" it is singly-bound Or it is not present;N=0,1,2,3 or 4；K=0,1,2,3 or 4；
Each R1, R3Can be identical or different, respectively it independently is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carboxylic Base, alkyl, halogenated alkyl, alkoxy, alkylamino, alkyl acyl, hydroxy alkoxy base, Hydroxyalkylamino, hydroxyl alkane Acyl group, halogenated alkoxy, halogenated alkylamino, ohaloalkanoyl, aminoalkoxy, naphthenic base, cycloalkyl oxy, ring Alkyl amino, cycloalkanoyl, alkenyl, alkenylalkoxy, alkenyl alkylamino, alkenyl alkanoyl, alkynyl, alkynyl alkane Oxygroup, alkynyl alkylamino, alkynyl alkanoyl, aryl, aryloxy group, aroyl, fragrant amino, alkoxy aryl, aryl Alkylamino, heteroaryl, heteroaryloxy, 4-hetaroylpyrazol, heteroaryl amino, heteroarylalkoxy, heteroarylalkylamino are miscellaneous Ring group alkanoyl, Heterocyclylalkyl, heterocycle oxygroup, heterocyclylamino group, heterocyclylacyl, heterocyclylalkoxy, heterocycle Base alkylamino, heterocycle alkanoyl, azido alkoxy, condensed-bicyclic base condense miscellaneous bicyclic group, condensed-bicyclic base fat Fat race, condensed miscellaneous bicyclic group aliphatic, condensed-bicyclic base oxygroup, condensed miscellaneous bicyclic group oxygroup, condensed-bicyclic base amino, Miscellaneous bicyclic group amino is condensed, condensed-bicyclic base alkoxy condenses miscellaneous bicyclic group alkoxy, and condensed-bicyclic base alkylamino is thick Miscellaneous bicyclic group alkylamino is closed, condensed-bicyclic base oxygroup alkoxy condenses miscellaneous bicyclic group oxygroup alkoxy, condensed-bicyclic base ammonia Base alkoxy, condenses miscellaneous bicyclic group aminoalkoxy, and condensed-bicyclic base-C (=O)-, condensed-bicyclic base-C (=O) O- are condensed Miscellaneous bicyclic group-C (=O)-condenses miscellaneous bicyclic group-C (=O) O-, condensed-bicyclic base amino-C (=O)-, condenses miscellaneous bicyclic group ammonia Base-C (=O)-, condensed-bicyclic base-C (=O) N (R4)-, condenses miscellaneous bicyclic group-C (=O) N (R4)-, spiral shell bicyclic group, spiral shell are miscellaneous double Ring group, spiral shell bicyclic group aliphatic, the miscellaneous bicyclic group aliphatic of spiral shell, spiral shell bicyclic group oxygroup, the miscellaneous bicyclic group oxygroup of spiral shell, spiral shell are bicyclic Base amino, the miscellaneous bicyclic group amino of spiral shell, spiral shell bicyclic group alkoxy, the miscellaneous bicyclic group alkoxy of spiral shell, spiral shell bicyclic group alkylamino, spiral shell Miscellaneous bicyclic group alkylamino, spiral shell bicyclic group oxygroup alkoxy, the miscellaneous bicyclic group oxygroup alkoxy of spiral shell, spiral shell bicyclic group aminoalkoxy, The miscellaneous bicyclic group aminoalkoxy of spiral shell, spiral shell bicyclic group-C (=O)-, spiral shell bicyclic group-C (=O) O-, the miscellaneous bicyclic group-C of spiral shell (=O)-, Miscellaneous bicyclic group-the C of spiral shell (=O) O-, spiral shell bicyclic group amino-C (=O)-, the miscellaneous bicyclic group amino-C of spiral shell (=O)-, spiral shell bicyclic group-C (= O)N(R4Miscellaneous bicyclic group-the C of)-, spiral shell (=O) N (R4)-, R5R4N-, -C(=O)NR4R5, -OC(=O)NR4R5, -OC(=O)OR4, -N(R4)C(=O)NR4R5, -N(R4)C(=O)OR5, -N(R4)C(=O)-R5, R4R5N-S(=O)t-, R4S(=O)t-, R4S(= O)tN(R5)-, R5R4N- alkyl, R4S(=O)tAlkyl, R4R5N-C (=O)-alkyl, R5R4N- alkoxies, R4S(=O)tAlkane Oxygroup, R4R5N-C (=O)-alkoxy, aryl-(CH2)p-G-(CH2)m, heteroaryl-(CH2)p-G-(CH2)m, heterocycle- (CH2)p-G-(CH2)m, or naphthenic base-(CH2)p-G-(CH2)m, wherein G is O, S, NR6, S(=O), S(=O)2,C(= O), -C(=O)N(R4)-, -OC(=O)N(R4)-, -OC(=O)-, -N(R4)C(=O)N(R4)-, -(R4)N-S(=O)t-, - OS(=O)t, or-OS (=O)tN(R4)-;T is l or 2;P and m is each independently 0, l, 2,3 or 4;Or it is wherein fragrant Base-(CH2)p-G-(CH2)m, heteroaryl-(CH2)p-G-(CH2)m, heterocycle-(CH2)p-G-(CH2)m, or naphthenic base- (CH2)p-G-(CH2)mCan F, Cl, Br, I, alkyl, alkenyl, alkynyl, alkoxy or cyanogen be selected from by one or more The substituent group of base replaces;
R2For hydrogen, alkyl, halogenated alkyl, alkyl acyl, hydroxyalkanoyl, ohaloalkanoyl, naphthenic base, naphthenic base acyl Base, alkenyl, alkenyl alkanoyl, alkynyl, alkynyl alkanoyl, aryl, aroyl, heteroaryl, 4-hetaroylpyrazol, heterocycle Base alkanoyl, Heterocyclylalkyl, heterocyclylacyl, heterocycle alkanoyl, azido alkyl, condensed-bicyclic base condense miscellaneous Bicyclic group, condensed-bicyclic base-C (=O)-condense miscellaneous bicyclic group-C (=O)-, and condensed-bicyclic base amino-C (=O)-is condensed miscellaneous Bicyclic group amino-C (=O)-, spiral shell bicyclic group, the miscellaneous bicyclic group of spiral shell, spiral shell bicyclic group aliphatic, the miscellaneous bicyclic group aliphatic of spiral shell, spiral shell Bicyclic group-C (=O)-, the miscellaneous bicyclic group-C of spiral shell (=O)-, spiral shell bicyclic group amino-C (=O)-, the miscellaneous bicyclic group amino-C of spiral shell (=O)-, -C(=O)NR4R5, R4R5N-S(=O)t-, R4S(=O)t-, R5R4N- alkyl, R4S(=O)tAlkyl, R4R5N-C (=O)-alkane Base, aryl-(CH2)p-G-(CH2)m, heteroaryl-(CH2)p-G-(CH2)m, heterocycle-(CH2)p-G-(CH2)m, or ring Alkyl-(CH2)p-G-(CH2)m, wherein G is O, S, NR6, S(=O), S(=O)2,C(=O), -C(=O)N(R4)-, -OC (=O)N(R4)-, -OC(=O)-, -N(R4)C(=O)N(R4)-, -(R4)N-S(=O)t-, -OS(=O)t, or-OS (=O)tN (R4)-;T is l or 2;P and m is each independently 0, l, 2,3 or 4;Or aryl-(CH therein2)p-G-(CH2)m-, Heteroaryl-(CH2)p-G-(CH2)m, heterocycle-(CH2)p-G-(CH2)m, or naphthenic base-(CH2)p-G-(CH2)mIt can be by One or more is selected from F, Cl, Br, I, cyano, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, carbon Ring group, the substituent group substitution of heterocycle;
R6Can be identical or different, it is each independently hydrogen, R4R5NC(=O)-, R4OC(=O)-, R4C(=O)-, R4R5NS(= O)-, R4OS(=O)-, R4S(=O)-, R4R5NS(=O)2-, R4OS(=O)2-, R4S(=O)2, aliphatic, halogenated aliphatic Race, hydroxyl group aliphatic, amino aliphatic, alkoxy aliphatic, alkylamino aliphatic, alkylthio group aliphatic, aryl fat Fat race, heteroaryl aliphatic, heterocycle aliphatic, naphthenic base aliphatic, aryloxy group aliphatic, heterocycle oxygroup fat Race, cycloalkyl oxy aliphatic, fragrant amino aliphatic, heterocyclylamino group aliphatic, cycloalkyl amino aliphatic, aryl, Heteroaryl, heterocycle or carbocylic radical;
Each R4And R5It independently is hydrogen, aliphatic, halogenated aliphatic, hydroxyl group aliphatic, amino aliphatic, alkoxy fat Race, alkylamino aliphatic, alkylthio group aliphatic, aromatic yl aliphat, heteroaryl aliphatic, heterocycle aliphatic, cycloalkanes Base aliphatic, aryloxy group aliphatic, heterocycle oxygroup aliphatic, cycloalkyl oxy aliphatic, fragrant amino aliphatic are miscellaneous Ring group amino aliphatic, cycloalkyl amino aliphatic, aryl, heteroaryl, heterocycle or naphthenic base;Work as R4And R5It is connected in same R on one nitrogen-atoms4, R5Substituted or non-substituted 3-6 membered rings can be randomly formed with nitrogen-atoms, condensed-bicyclic or spiral shell are double Ring;The hetero atom in heterocycle, heteroaryl, condensed miscellaneous bicyclic group, the miscellaneous bicyclic group of spiral shell involved in above-mentioned group is independently to select From 1-5 hetero atom in N, O, S, Se;
Above-mentioned R1, R2, R3, R4, R5, R6Group can appoint by deuterium, halogen, hydroxyl, methylol, carboxyl, acetylamino, Alkyl（Such as methyl, ethyl, propyl）, alkoxy（Such as methoxyl group, ethyoxyl, tert-butoxy）, alkylamino, naphthenic base, alkene Base, alkynyl, trifluoromethyl, trifluoroacetyl group, sulfydryl, halogen, nitro, amino, azido (- N3), guanidine radicals, Cyano, tertbutyloxycarbonyl (- Boc), carbonyl (- C=O), oxo (=O) is thio (=S), sulfonyl, and aryl is miscellaneous Aryl, the substitution of one or more of heterocycle.
2. compound according to claim 1 is general formula III-X compounds represented, or chemical combination shown in general formula III-X The stereoisomer geometric isomer of object, tautomer, nitrogen oxides, raceme, hydrate, solvate, metabolite, Pharmaceutically acceptable salt or prodrug：
,
Wherein T1, T2, T3, T4Separate is CR1Or N, V1, V2, V3, V4Separate is CR3Or N, wherein T1, T2, T3, T4At most there are three can be N, V1, V2, V3, V4At most can there are two be N, "" indicate singly-bound Or it is not present;Each R1, R2, R3As follows：
Each R1, R3Can be identical or different, it is each independently H, F, Cl, Br, I, hydroxyl, amino, nitro, cyanogen Base, carboxyl, C1-C20 alkyl, C1-C20 halogenated alkyls, C1-C20 alkoxies, C1-C20 alkylaminos, C1-C20 alkyl Acyl group, hydroxyl C1-C20 alkoxies, hydroxyl C1-C20 alkylaminos, hydroxyl C1-C20 alkanoyls, C1-C20 halogenated alkoxies, The halogenated alkylaminos of C1-C20, C1-C20 ohaloalkanoyls, C1-C20 aminoalkoxies, C3-C10 naphthenic base, C3-C10 rings Alkyl oxy, C3-C10 cycloalkyl aminos, C3-C10 cycloalkanoyls, C2-C8 alkenyls, C2-C8 alkynyls, C6-C10 virtues Base, C6-C10 aryloxy group, C6-C10 aroyls, C6-C10 fragrant aminos, C6-C10 aryl C1-C6 alkoxies, C6-C10 virtues Base alkylamino, C5-C12 heteroaryls, C5-C12 heteroaryloxies, C5-C12 4-hetaroylpyrazols, C5-C12 heteroaryl amino, C5- C12 heteroaryl C1-C6 alkoxies, C5-C12 heteroaryl C1-C6 alkylaminos, C4-C12 heterocycle C1-C6 alkanoyls, C4- C12 Heterocyclylalkyls, C4-C12 heterocycle oxygroups, C4-C12 heterocyclylamino groups, C4-C12 heterocyclylacyls, C4-C12 heterocycles Base C1-C6 alkoxies, C4-C12 heterocycle C1-C6 alkylaminos, C4-C12 heterocycle C1-C6 alkanoyls, R5R4N-, -C(= O)NR4R5, -OC(=O)NR4R5, -OC(=O)OR4, -N(R4)C(=O)NR4R5, -N(R4)C(=O)OR5, -N(R4)C(=O)- R5, R4R5N-S(=O)t-, R4S(=O)t-, R4S(=O)tN(R5)-, R5R4N-C1-C6 alkyl, R4S(=O)t- C1-C6 alkane Base, R4R5N-C (=O)-C1-C6 alkyl, R5R4N-C1-C6 alkoxies, R4S(=O)t- C1-C6 alkoxies, R4R5N-C(=O)- C1-C6 alkoxies, C6-C10 aryl-(CH2)p-G-(CH2)m, C5-C12 heteroaryls-(CH2)p-G-(CH2)m-, C4-C12 Heterocycle-(CH2)p-G-(CH2)m, or C3-C10 naphthenic base-(CH2)p-G-(CH2)m, wherein G is O, S, NR6, S(= O), S(=O)2,C(=O), -C(=O)N(R4)-, -OC(=O)N(R4)-, -OC(=O)-, -N(R4)C(=O)N(R4)-, - (R4)N-S(=O)t-, -OS(=O)t, or-OS (=O)tN(R4)-；T is l or 2；P and m be each independently 0, l, 2,3 or 4；Or wherein C6-C10 aryl-(CH2)p-G-(CH2)m, C5-C12 heteroaryls-(CH2)p-G-(CH2)m, C4-C12 heterocycles Base-(CH2)p-G-(CH2)m, or C3-C1 naphthenic base-(CH2)p-G-(CH2)mCan F, Cl be selected from by one or more, The substituent group of Br, I, alkyl, alkenyl, alkynyl, alkoxy or cyano replaces;
R2It is each independently H, C1-C20 alkyl, C1-C20 halogenated alkyls, C1-C20 alkyl acyls, C1-C20 hydroxyl alkane Acyl group, C1-C20 ohaloalkanoyls, C3-C10 naphthenic base, C3-C10 cycloalkanoyls, C2-C8 alkenyls, C2-C8 alkenyls Alkanoyl, C2-C8 alkynyls, C2-C8 alkynyl alkanoyls, C6-C10 aryl, C6-C10 aroyls, C5-C12 heteroaryls, C5-C12 4-hetaroylpyrazols, C4-C12 heterocycle alkanoyls, C4-C12 Heterocyclylalkyls, C4-C12 heterocyclylacyls, C4-C12 Heterocycle C1-C6 alkanoyls, C5-C12 condensed-bicyclic bases, C5-C12 condense miscellaneous bicyclic group ,-C (=O) NR4R5, R4R5N-S (=O)t-, R4S(=O)t-, R5R4N-C1-C6 alkyl, R4S(=O)t- C1-C6 alkyl, R4R5N-C (=O)-C1-C6 alkyl, C6-C10 aryl-(CH2)p-G-(CH2)m, C5-C12 heteroaryls-(CH2)p-G-(CH2)m, C4-C12 heterocycles-(CH2)p- G-(CH2)m, or C3-C10 naphthenic base-(CH2)p-G-(CH2)m, wherein G is O, S, NR8, S(=O), S(=O)2,C(= O), -C(=O)N(R4)-, -OC(=O)N(R4)-, -OC(=O)-, -(R4)N-S(=O)t-, -OS(=O)t, or-OS (= O)tN(R4)-；T is l or 2；P and m is each independently 0, l, 2,3 or 4；Or wherein C6-C10 aryl-(CH2)p-G- (CH2)m, C5-C12 heteroaryls-(CH2)p-G-(CH2)m, C4-C12 heterocycles-(CH2)p-G-(CH2)m, or C3-C10 Naphthenic base-(CH2)p-G-(CH2)mCan F, Cl, Br, I, cyano, alkyl, alkenyl, alkynes be selected from by one or more Base, alkoxy, aryl, heteroaryl, carbocylic radical, the substituent group substitution of heterocycle;
Wherein each R6Can be identical or different, it is each independently H, R4R5NC(=O)-, R4OC(=O)-, R4C(=O)-, R4R5NS(=O)-, R4OS(=O)-, R4S(=O)-, R4R5NS(=O)2-, R4OS(=O)2-, R4S(=O)2, C1-C3 fat Race, C1-C3 halogenated aliphatics, C1-C3 hydroxyl group aliphatics, C1-C3 amino aliphatic, C1-C3 alkoxy Cs 1-C3 fat Race, C1-C3 alkylamino C1-C3 aliphatic, C1-C3 alkylthio group C1-C3 aliphatic, C6-C10 aryl C1-C3 aliphatic, C5-C9 heteroaryl C1-C3 aliphatic, C4-C10 heterocycle C1-C3 aliphatic, C3-C10 naphthenic base C1-C3 aliphatic, C6- C10 aryloxy group C1-C3 aliphatic, C4-C10 heterocycle oxygroup C1-C3 aliphatic, C3-C10 cycloalkyl oxies C1-C3 fat Race, C6-C10 fragrant amino C1-C3 aliphatic, C4-C10 heterocyclylamino group C1-C3 aliphatic, C3-C10 cycloalkyl aminos C1- C3 aliphatic, C6-C10 aryl, C5-C10 heteroaryls, C4-C10 heterocycles or C3-C10 naphthenic base;
Wherein each R4And R5It independently is H, C1-C3 aliphatic, C1-C3 halogenated aliphatics, C1-C3 hydroxyl group aliphatics, C1- C3 amino aliphatic, C1-C3 alkoxy C 1-C3 aliphatic, C1-C3 alkylamino C1-C3 aliphatic, C1-C3 alkylthio groups C1- C3 aliphatic, C6-C10 aryl C1-C3 aliphatic, C5-C9 heteroaryl C1-C3 aliphatic, C4-C10 heterocycle C1-C3 fat Fat race, C3-C10 naphthenic base C1-C3 aliphatic, C6-C10 aryloxy group C1-C3 aliphatic, C4-C10 heterocycle oxygroups C1-C3 Aliphatic, C3-C10 cycloalkyl oxy C1-C3 aliphatic, C6-C10 fragrant amino C1-C3 aliphatic, C4-C10 heterocycle ammonia Base C1-C3 aliphatic, C3-C10 cycloalkyl amino C1-C3 aliphatic, C6-C10 aryl, C5-C10 heteroaryls, C4-C10 Heterocycle or C3-C10 naphthenic base；Work as R4And R5It is connected on the same nitrogen-atoms, R4, R5It can be randomly formed with nitrogen-atoms Substituted or non-substituted 3-6 membered rings;
Above-mentioned R1, R2, R3, R4, R5, R6Group can appoint by deuterium, halogen, hydroxyl, methylol, carboxyl, acetylamino, Alkyl（Such as methyl, ethyl, propyl）, alkoxy（Such as methoxyl group, ethyoxyl, tert-butoxy）, alkylamino, naphthenic base, alkene Base, alkynyl, trifluoromethyl, trifluoroacetyl group, sulfydryl, halogen, nitro, amino, azido (- N3), guanidine radicals, Cyano, tertbutyloxycarbonyl (- Boc), carbonyl (- C=O), oxo (=O) is thio (=S), sulfonyl, and aryl is miscellaneous Aryl, the substitution of one or more of heterocycle.
3. according to compound described in claim 1-2, wherein each R1, R3Can be identical or different, it is each independently H, D, F, Cl, Br, I, hydroxyl, amino, nitro, cyano, methyl, ethyl, propyl, isopropyl, butyl, tertiary butyl, C5H11, C6H13, C8H17, trifluoromethyl, hydroxymethyl, amino methyl, methoxyl group, ethyoxyl, tert-butoxy, first Amino, ethylamino, isopropylamino, 3- hydroxyl-propyls, acetyl group, trifluoroacetyl group, Cyanoacetyl, methylamino Acetyl group, propiono, iso-propionyl, 2- hydroxypropanoyls, 2- aminopropionyls, 2- chlorine propionos, 2- bromine propionos, Valeryl, caproyl, heptanoyl group, methacrylyl, phenyl, benzoyl, p-nitrophenyl, to toluyl Base, fluoro benzoyl, p-benzoyl base, to methoxybenzoyl base, 2,4- dimethylbenzoyls are folded Nitrogen base benzoyl, benzyl, p-chlorobenzyl, vinyl, acrylic, allyl, n-butene base, isobutenyl, just Pentenyl, isopentene group, cyclopropyl, ring propiono, ring valeryl, cyclohexanoyl, 3- picolinoyls, naphthalene, Phenethyl imidazole radicals, pyridyl group, pyrrole radicals, oxazolyl, isoxazolyls, triazol radical, tetrazole base, furyl, Thienyl, thiazolyl, piperidyl, piperazinyl, indyl, carbazyl, benzofuranyl tetrahydrofuran base, tetrahydrochysene pyrrole It mutters base, pyrimidine bases, purine bases ,-N (CH3)2,-C (C=O) NH-C1-C4 alkyl ,-OC (C=O)-NH-C1-C4 alkane Base ,-OC (O=O) O-C1-C4 alkyl ,-NHC (=O) NH-C1-C4 alkyl ,-NHC (=O) O-C1-C4 alkyl ,-NHC (=O)- C1-C4 alkyl, C1-C4 alkyl-NH-S (=O)2, C1-C4 alkyl S (=O)2, C1-C4 alkyl S (=O)2NH-, phenyl- (CH2)P-G-(CH2)m, difluorophenyl-(CH2)P-G-(CH2)m, thiazolyl-(CH2)p-G-(CH2)m, pyridyl group- (CH2)p-G-(CH2)m, phenylethyl, cyclohexyl-(CH2)p-G-(CH2)m, wherein G is O, S, S (=O), S (= O)2, C(=O);P and m is each independently 0,1,2 or 3;Or wherein C6-C10 aryl-(CH2)P-G-(CH2)mIt can be with F, Cl, Br, I, methyl, ethyl, propyl, acetenyl, propinyl, butynyl, methoxy are selected from by one or more The substituent group of base, ethyoxyl or cyano replaces;Or above-mentioned R1, R3It is welcome by D, F, Cl, Br, I, hydroxyl, Methylol, carboxyl, acetylamino, alkyl（Such as methyl, ethyl, propyl）, alkoxy（Such as methoxyl group, ethyoxyl, tertiary fourth oxygen Base）, alkylamino, naphthenic base, alkenyl, alkynyl, trifluoromethyl, trifluoroacetyl group, sulfydryl, halogen, nitro, ammonia Base, azido (- N3), guanidine radicals, cyano, tertbutyloxycarbonyl (- Boc), carbonyl (- C=O), oxo (=O) is thio (=S), sulfonyl, aryl, heteroaryl, the substitution of one or more of heterocycle;
Each R2Can be identical or different, it is each independently H, methyl, ethyl, propyl, isopropyl, butyl, tertiary butyl, C5H11, C6H13, C8H17, trifluoromethyl, hydroxymethyl, amino methyl, 3- hydroxyl-propyls, acetyl group, trifluoroacetyl Base, Cyanoacetyl, methylamino acetyl group, propiono, iso-propionyl, 2- hydroxypropanoyls, 2- aminopropionyls, 2- chlorine propionos, 2- bromine propionos, valeryl, caproyl, heptanoyl group, methacrylyl, phenyl, benzoyl, P-nitrophenyl, to methyl benzoyl, fluoro benzoyl, p-benzoyl base, to methoxybenzoyl base, 2,4- dimethylbenzoyls, azidobenzoyl, benzyl, p-chlorobenzyl, vinyl, acrylic, allyl, N-butene base, isobutenyl, n-pentene base, isopentene group, cyclopropyl, ring propiono, ring valeryl, cyclohexanoyl, 3- picolinoyls, naphthalene, phenethyl imidazole radicals, pyridyl group, pyrrole radicals, oxazolyl, isoxazolyls, triazol radical, Tetrazole base, furyl, pyranose, thienyl, thiazolyl, piperidyl, piperazinyl, indyl, carbazyl, benzene And furyl tetrahydrofuran base, THP trtrahydropyranyl, pyrimidine bases, purine bases, pentose base, hexose base ,-(C= O) NH-C1-C4 alkyl, C1-C4 alkyl-NH-S (=O)2, C1-C4 alkyl S (=O)2, phenyl-(CH2)P-G-(CH2)m-, Difluorophenyl-(CH2)P-G-(CH2)m, thiazolyl-(CH2)p-G-(CH2)m, pyridyl group-(CH2)p-G-(CH2)m, phenyl Ethyl, cyclohexyl-(CH2)p-G-(CH2)m, wherein G is O, S, S (=O), S (=O)2, C(=O);P and m are respectively only It is on the spot 0,1,2 or 3;Or wherein C6-C10 aryl-(CH2)P-G-(CH2)mCan F be selected from by one or more, Cl, Br, I, methyl, ethyl, propyl, acetenyl, propinyl, butynyl, methoxyl group, ethyoxyl or cyano Substituent group replaces;Or above-mentioned R2It is welcome by D, F, Cl, Br, I, hydroxyl, hydroxyl, methylol, carboxyl, acetyl Amino, C1-C6 alkyl（Such as methyl, ethyl, propyl）, C1-C6 alkoxies, C1-C6 alkylaminos, trifluoromethyl, trifluoro second Acyl group, sulfydryl, nitro, amino, azido (- N3), guanidine radicals, cyano, tertbutyloxycarbonyl (- Boc), carbonyl (- C= ), O oxo (=O), thio (=S), sulfonyl, the substitution of one or more of phenyl.
4. according to compound described in claim 1-3, include the tautomerism of one of following structure or following one structure Body, racemic modification, the non-equal amount of mixture of enantiomter, geometric isomer, solvate, pharmaceutically may be used at stereoisomer The solvate of the salt of receiving or its salt, or prodrug:
。
5. claim 1-4 any one of them pharmaceutically acceptable salts are selected from：Hydrochloride, sulfate, phosphate, oxalic acid Salt, maleate, methane sulfonates, succinate, citrate, fumarate, glucuronate salt, formates, acetate, Succinate;The solvate of solvate or salt is selected from:Monohydrate, dihydrate, trihydrate, a methanol solvate, Diformazan alcohol adduct, an acetonitrile close object, diacetonitrile closes object, an acetone closes object, two acetone close object, hemifumarate monohydrate, richness Horse hydrochlorate dihydrate, one ethanolates of fumarate;It is preferred that monohydrate, fumarate dihydrate, one second of fumarate Alcohol adduct.
6. a kind of pharmaceutical composition, it includes according to a kind of compound of claim 1-5 any one of them or several compounds Or the non-equal amount of mixture of its tautomer, stereoisomer, racemic modification, enantiomter, geometric isomer, solvation Any one or a few in the solvate of object, pharmaceutically acceptable salt or its salt is as active ingredient.
7. the pharmaceutical composition described in claim 6, it is characterised in that the pharmaceutical composition also includes that at least one pharmaceutically may be used Carrier, diluent or the excipient of receiving.
8. the pharmaceutical composition described in claim 7, it is characterised in that the pharmaceutical composition, which also includes at least one other, to be had Immunoloregulation function and anti-inflammatory, anti-fibrosis drug, are specifically including but not limited to, and imuran, sprinkles Buddhist nun at cyclophosphamide Pine, prednisolone, aspirin, paracetamol, Indomethacin, naproxen, Nabumetone, Diclofenac, brufen, Ni Mei Shu Li, rofecoxib, celecoxib, levamisol, interleukins, interferon, transfer factor, thymosin extrasin, antilymphocyte Globulin, cyclosporine, Mycophenolate Mofetil etc.;Pharmaceutical composition optimizing injection, oral preparation, freeze drying powder injection, the suspending agent Deng.
9. compound or its tautomer, its stereoisomer, its racemic modification described in any one of claim 1-5, The non-equal amount of mixture of its enantiomter, its geometric isomer, its solvate, its pharmaceutically acceptable salt or its salt Pharmaceutical composition described in any one of solvate or claim 6-8 is used to prepare with immunoloregulation function and resists The purposes of scorching, anti-fibrosis drug.
10. compound or its tautomer, its stereoisomer, its racemic modification described in any one of claim 1-5, The non-equal amount of mixture of its enantiomter, its geometric isomer, its solvate, its pharmaceutically acceptable salt or its salt Pharmaceutical composition described in any one of solvate or claim 6-8 is preparing treatment and/or is preventing by inflammation, siberian crabapple Application in the drug of disease caused by system imbalance etc.;The disease select kidney region fibrosis, glomerulosclerosis, liver fibrosis, Pulmonary fibrosis, peritoneal fibrosiss, myocardial fibrosis, fibrosis of skin, postoperative intestinal adhesion, benign prostatauxe disease, skeletal muscle Fibrosis, chorionitis, multiple sclerosis, pancreatic fibrosis, hepatic sclerosis, muscle tumor, nerve fibre onch- interstitial fibrosis, Diabetic nephropathy, Alzheimer disease, vascular fibrosis, serous inflammation, fibrinous inflammation, suppurative inflammation, hemorrhagic inflammation, necrosis Property inflammation, catarrhal inflammation, tuberculosis, syphilis, leprosy, poradenia, allergy, rheumatoid arthritis, rheumatoid heart disease, Chinese mugwort Grow disease, delayed immunological disease, cell toxicant type immunological disease, neurodegenerative disease etc..
11. compound or its tautomer, its stereoisomer, its racemic modification described in any one of claim 1-5, The non-equal amount of mixture of its enantiomter, its geometric isomer, its solvate, its pharmaceutically acceptable salt or its salt The purposes of pharmaceutical composition in medicine preparation described in any one of solvate or claim 6-8;The drug is used for Treatment by tumor necrosis factor (TNF-a), interleukin-β, lipopolysaccharides (LPS), oxidant, radioactive ray, ultraviolet light, virus and its The factors such as metabolite activate immune dysfunction diseases caused by NF- κ Factor Bs.
12. compound or its tautomer, its stereoisomer, its racemic modification described in any one of claim 1-5, The non-equal amount of mixture of its enantiomter, its geometric isomer, its solvate, its pharmaceutically acceptable salt or its salt Application of the solvate in preparing the active lead compound for inhibiting NF- κ Factor Bs.
CN201710191160.2A 2017-03-28 2017-03-28 A kind of alkaloid compound and application containing double lactams Pending CN108658985A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710191160.2A CN108658985A (en) 2017-03-28 2017-03-28 A kind of alkaloid compound and application containing double lactams

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710191160.2A CN108658985A (en) 2017-03-28 2017-03-28 A kind of alkaloid compound and application containing double lactams

Publications (1)

Publication Number Publication Date
CN108658985A true CN108658985A (en) 2018-10-16

Family

ID=63785785

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710191160.2A Pending CN108658985A (en) 2017-03-28 2017-03-28 A kind of alkaloid compound and application containing double lactams

Country Status (1)

Country Link
CN (1) CN108658985A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426499A (en) * 2006-02-22 2009-05-06 弗特克斯药品有限公司 Modulators of muscarinic receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426499A (en) * 2006-02-22 2009-05-06 弗特克斯药品有限公司 Modulators of muscarinic receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OLEG V. ERSHOV 等: "2-Pyridone-based fluorophores: Synthesis and fluorescent properties of pyrrolo[3,4-c]pyridine derivatives", 《DYES AND PIGMENTS》 *

Similar Documents

Publication Publication Date Title
CN105294683B (en) Compound of CDK type small molecular inhibitors and application thereof
CN108658972A (en) A kind of substituted lactams compounds and its preparation method and application
CN105503862B (en) Inhibitors of influenza viruses replication
CN104513252B (en) Substituted urea derivative and its application in medicine
CN103570630B (en) Nitrogen heterocyclic derivative and the application in medicine thereof
CN105384687B (en) Quinolinones compound and its applied in medicine
EP3027614A1 (en) Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases
CN106478607B (en) Substituted heteroaryl compound and combinations thereof and purposes
CN106456653A (en) Treatment of conditions associated with hyperinsulinaemia
CN110511219A (en) The dihydronaphthridine class compound and application thereof that phenyl replaces
CN106068256A (en) For treating benzodiazepine * derivant, compositions and the method for cognitive impairment
CN108658974A (en) A kind of lactam analog compound and its preparation method and application
CN105461693B (en) CRTH2 agonist compounds and application thereof
CN109776522A (en) Substituted heteroaryl compound and combinations thereof and purposes
CN103539777A (en) PI3 kinase regulator as well as use method and application of PI3 kinase regulator
CN103965199B (en) A kind of heteroaromatic compounds, the medical composition and its use comprising it
CN104725356A (en) Nitrogen heterocyclic derivatives and application thereof in medicine
CN104177363A (en) Bicyclic heterocyclic amine Hedgehog signal pathway inhibitor
CN109988106A (en) The aminated compounds for inhibiting SSAO/VAP-1 and its application in medicine
CN104650070B (en) Dihydropyrimidines and its application in drug
CN104974163A (en) Substituted heteroaryl compound, composition thereof, and applications thereof
CN104761507B (en) Amido quinazoline derivatives and its application in drug
AU2013318672A1 (en) Means and method for treating solid tumours
CN108658937A (en) A kind of bicyclic alkaloid compound and its preparation method and application
CN104672250A (en) Substituted ceteroary compound as well as composition and purpose thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181016